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Background: Interventional pain management involves diagnosis and treatment of chronic 
pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central 
nervous system and the spinal column. A subset of patients encountered in interventional pain are 
medicated using anticoagulant or antithrombotic drugs to mitigate thrombosis risk. Since these 
drugs target the clotting system, bleeding risk is a consideration accompanying interventional 
procedures. Importantly, discontinuation of anticoagulant or antithrombotic drugs exposes 
underlying thrombosis risk, which can lead to significant morbidity and mortality especially in those 
with coronary artery or cerebrovascular disease. This review summarizes the literature and provides 
guidelines based on best evidence for patients receiving anti-clotting therapy during interventional 
pain procedures. 
Study Design: Best evidence synthesis.
Objective: To provide a current and concise appraisal of the literature regarding an assessment 
of the bleeding risk during interventional techniques for patients taking anticoagulant and/or 
antithrombotic medications. 
Methods: A review of the available literature published on bleeding risk during interventional pain 
procedures, practice patterns and perioperative management of anticoagulant and antithrombotic 
therapy was conducted. Data sources included relevant literature identified through searches of 
EMBASE and PubMed from 1966 through August 2018 and manual searches of the bibliographies 
of known primary and review articles.
Results: 
1. There is good evidence for risk stratification by categorizing multiple interventional 
techniques into low-risk, moderate-risk, and high-risk. Also, their risk should be up-
graded based on other risk factors.
2. There is good evidence for the risk of thromboembolic events in patients who inter-
rupt antithrombotic therapy. 
3. There is good evidence supporting discontinuation of low dose aspirin for high risk 
and moderate risk procedures for at least 3 days, and there is moderate evidence that 
these may be continued for low risk or some intermediate risk procedures.
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4. There is good evidence that discontinuation of anticoagulant therapy with warfarin, heparin, dabigatran 
(Pradaxa®), argatroban (Acova®), bivalirudin (Angiomax®), lepirudin (Refludan®), desirudin (Iprivask®), hirudin, 
apixaban (Eliquis®), rivaroxaban (Xarelto®), edoxaban (Savaysa®, Lixiana®), Betrixaban(Bevyxxa®), fondaparinux 
(Arixtra®) prior to interventional techniques with individual consideration of pharmacokinetics and pharmacody-
namics of the drugs and individual risk factors increases safety.
5. There is good evidence that diagnosis of epidural hematoma is based on severe pain at the site of the injection, 
rapid neurological deterioration, and MRI with surgical decompression with progressive neurological dysfunction 
to avoid neurological sequelae.
6. There is good evidence that if thromboembolic risk is high, low molecular weight heparin bridge therapy can be 
instituted during cessation of the anticoagulant, and the low molecular weight heparin can be discontinued 24 
hours before the pain procedure.
7. There is fair evidence that the risk of thromboembolic events is higher than that of epidural hematoma for-
mation with the interruption of antiplatelet therapy preceding interventional techniques, though both risks are 
significant.
8. There is fair evidence that multiple variables including anatomic pathology with spinal stenosis and ankylosing 
spondylitis; high risk procedures and moderate risk procedures combined with anatomic risk factors; bleeding 
observed during the procedure, and multiple attempts during the procedures increase the risk for bleeding com-
plications and epidural hematoma.
9. There is fair evidence that discontinuation of phosphodiesterase inhibitors is optional (dipyridamole [Persantine], 
cilostazol [Pletal]. However, there is also fair evidence to discontinue Aggrenox [dipyridamole plus aspirin]) 3 days 
prior to undergoing interventional techniques of moderate and high risk. 
10. There is fair evidence to make shared decision making between the patient and the treating physicians with the 
treating physician and to consider all the appropriate risks associated with continuation or discontinuation of 
antithrombotic or anticoagulant therapy.
11. There is fair evidence that if thromboembolic risk is high antithrombotic therapy may be resumed 12 hours after 
the interventional procedure is performed.
12. There is limited evidence that discontinuation of antiplatelet therapy (clopidogrel [Plavix®], ticlopidine [Ti-
clid®], Ticagrelor [Brilinta®] and prasugrel [Effient®]) avoids complications of significant bleeding and epidural 
hematomas.
13. There is very limited evidence supporting the continuation or discontinuation of most NSAIDs, excluding aspirin, 
for 1 to 2 days and some 4 to 10 days, since these are utilized for pain management without cardiac or cerebral 
protective effect.
Limitations: The continued paucity of the literature with discordant recommendations.
Conclusion: Based on the survey of current literature, and published clinical guidelines, recommendations for patients presenting 
with ongoing antithrombotic therapy prior to interventional techniques are variable, and are based on comprehensive analysis of 
each patient and the risk-benefit analysis of intervention.
Key words: Perioperative bleeding, bleeding risk, practice patterns, anticoagulant therapy, antithrombotic therapy, interventional 
techniques, safety precautions, pain
Disclaimer: These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body 
of evidence, this document is not intended to be a “standard of care.” 
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1.0 IntroductIon
With the increasing use of prescription medications to manage thrombosis risk and the ease of availability of over-the-
counter and herbal products that mediate or modulate 
the coagulation cascade (1-21), and techniques to 
manage chronic pain, interventional pain physicians 
frequently encounter the challenge of potential risk of 
bleeding or thrombosis in perioperative management 
of these patients (1,13,14,20,22-54). Modulation of 
anticoagulant and antithrombotic therapy during 
performance of interventional techniques is one of 
the major clinical decisions often made without precise 
evidence-based literature to support existing opinions 
(1,13,14,20,31-54). Leading causes of morbidity and 
mortality worldwide include cardiovascular and 
cerebrovascular disease (4,5,55-58). In addition, one 
of the leading causes of disability and functional 
impairment across the globe is chronic persistent 
pain (29,30,59-66). Therefore, overlap between 
chronic persistent pain and cardiovascular disease 
has a synergistic impact on physical and psychological 
health, affecting performance of social responsibilities, 
including work and family life. Antithrombotic therapy 
has a clear evidence-based foundation with a favorable 
risk-benefit profile for prevention and management of 
cardiovascular disease, including limiting the present 
and future burden of cardiac or cerebrovascular 
infarcts (4,5,15-19,55-58,67-81). Of note, a significant 
proportion of patients with established cerebrovascular, 
cardiovascular or peripheral vascular disease who are 
receiving antithrombotic therapy, are commonly in need 
of interventions including surgery and interventional 
pain management techniques, despite the debate 
regarding their safety, clinical and cost effectiveness, 
and indications with numerous regulations (1,22-30,81-
121). 
Based on a survey of common practices by a major-
ity of interventional pain physicians, discontinuation of 
antiplatelet therapy and anticoagulant therapy is com-
mon (31). The results of this survey showed discontinu-
ation rate of warfarin therapy 100%, clopidogrel 97%, 
ticlopidine 96%, Aggrastat or tirofiban 95%, cilostazol 
93%, dipyridamole 85%, aspirin 350 mg 60%, aspirin 
81 mg 39%, and other nonsteroidal anti-inflammatory 
drugs (NSAIDs) 39% prior to performing interventional 
pain management techniques. The majority of physi-
cians accepted an international normalized ratio (INR) 
of 1.5 or less as a safe level. In another survey performed 
in 2012 by the American Society of Regional Anesthesia 
and Pain Medicine (ASRA), 55% stopped aspirin before 
spinal cord stimulation trials and implants, and 32% 
stopped before epidural steroid injections (40). The 
results of this study showed that only 36% knew that 
selective serotonin reuptake inhibitors (SSRIs) may lead 
to a bleeding disorder. Further, 17% utilized different 
protocols for cervical spine injections as compared with 
lumbar spine injections. This study (40) also showed 
that most physicians (88%) expressed the need for pain 
physicians to communicate with other physicians. 
Based on published guidelines, derived by clinical 
case reports and consensus, a large subset of clinicians 
report stopping antiplatelet therapy and consider this 
concept as a standard of care (1,20,33,36-38,122-129). 
Although the overall incidence of bleeding complica-
tions and epidural hematoma in the non-obstetric 
epidural literature has been reduced, the incidence 
has been higher with procedures involving cervical and 
thoracic spine (1,31-42,52-54,129). Of note, the clinical 
literature reports of incidences of epidural hematoma 
cases accompanying interventional techniques and 
neuraxial techniques are increasing rapidly (1,20,31-
42,130-149). While some reports indicate a decreas-
ing incidence of bleeding complications related to 
neuraxial techniques (145), multiple studies have been 
performed assessing the prevalence and risks related to 
bleeding complications and epidural hematoma with 
neuraxial procedures, specifically interventional tech-
niques (1,20,31-42,50,51,138-149).
Significant risks of withdrawing antiplatelet 
therapy include cardiovascular, cerebrovascular, and 
peripheral vascular thrombosis. In addition, the risks 
are higher in chronic pain patients as chronic psychoso-
cial stress causes a hypercoagulable state, as reflected 
by increased procoagulant molecular fibrinogen (or 
coagulation factor 7), reduced fibrinolytic capacity and 
increased platelet activity (40,150-152). Stress has been 
shown to affect coagulation activity via an influence 
on the regulation of genes coding for coagulation and 
fibrinolysis molecules (152) with increase in hormonal 
levels (153-155) and an underlying surge of catechol-
amine and cortisol induced hypercoagulability (155). A 
prior systematic review and meta-analysis explored the 
hazards of discontinuing or altering aspirin regimens 
among patients at risk for coronary artery disease (69). 
Importantly, in patients at moderate to high risk for 
coronary artery disease, withdrawal or noncompliance 
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with aspirin therapy was associated with 3-fold higher 
risk of major adverse cardiac events and the risk was 
magnified in patients with coronary stents. The findings 
support the recommendation that aspirin discontinu-
ation in this patient population should be advocated 
only under circumstances where the risk of adverse out-
comes caused by bleeding risk clearly outweighs that of 
catastrophic atherothrombotic events. These findings 
have been confirmed in later studies (70-78,150). Con-
versely, recently published large-scale evidence (15-19) 
shows lack of benefit of aspirin for primary prevention 
of cardiovascular events, but aspirin therapy is associ-
ated with increased bleeding episodes. Thus, current 
evidence suggests that the risks of coronary events 
related to patients abstaining from their antiplatelet 
medications during the perioperative period are more 
serious when compared to the risks of continuing anti-
platelet therapy through the perioperative period.
Multiple publications (1,32,33,42,46,138,140) have 
also supported the concept of continuing antiplatelet/
anticoagulant agents in patients undergoing various 
interventional pain procedures in light of identical 
complication rates as compared to the patients who 
stop taking these for a particular recommended period. 
It should be noted that there are only a few clinical 
reports of an epidural hematoma available in patients 
undergoing interventional therapies for chronic pain, 
which included patients both continuing and discon-
tinuing antithrombotic therapy. 
The American Society of Interventional Pain Physi-
cians (ASIPP) has developed multiple guidelines, both 
for interventional techniques and opioids (29,66,82). 
Consequently, the present investigation has been un-
dertaken to develop responsible, safe, and effective 
guidelines for patients on antithrombotic and antico-
agulant therapy undergoing interventional techniques. 
These guidelines offer an overview of the current 
literature applicable to antithrombotic and anticoagu-
lant therapy and the related complications, with incor-




Interventional pain management physicians pro-
vide a significant number of multidisciplinary strate-
gies including physical therapy, behavioral treatments, 
pharmacological, and interventional management 
to patients with chronic pain. The National Uniform 
Claims Committee (NUCC) defined interventional pain 
management as the discipline of medicine devoted 
to the diagnosis and treatment of pain-related disor-
ders, principally with the application of interventional 
techniques in managing subacute, chronic, persistent, 
and intractable pain, independently or in conjunction 
with other modalities of treatment (156). In addition, 
the Medicare Payment Advisory Commission (MedPAC) 
defined interventional pain management techniques as 
minimally invasive procedures including, percutaneous 
precision needle placement with placement of drugs 
in targeted areas or ablation of targeted nerves; and 
some surgical techniques such as laser or endoscopic 
discectomy, intrathecal infusion pumps and spinal cord 
stimulators, for the diagnosis and management of 
chronic, persistent or intractable pain (157).
Chronic spinal pain is a complex and multifacto-
rial phenomenon. Interventional pain physicians are 
familiar with various pathophysiologic, anatomic, and 
technical aspects of multiple interventional techniques 
applied in managing chronic pain. 
2.2 Objectives 
The objectives of these guidelines are to synthesize 
the available evidence on the safety, as well as adverse 
effects of antithrombotic and anticoagulant therapy 
for patients undergoing interventional techniques in 
the treatment of chronic spinal pain, and provide a 
rational and systematic approach to their application. 
2.3 Adherence to Trustworthy Standards
In preparation of these guidelines to develop re-
sponsible, safe, and effective guidelines for patients 
on antithrombotic and anticoagulant therapy un-
dergoing interventional techniques, the Institute of 
Medicine (IOM) standards and the National Guideline 
Clearinghouse Extent Adherence to Trustworthy Stan-
dards (NEATS) instruments were followed (158-160). 
The NEATS instrument was developed and tested as 
a tool to be used by the trained staff at the Agency 
for Healthcare Research and Quality (AHRQ) National 
Guideline Clearinghouse to provide assessment focused 
on adherence. 
2.3.1 Disclosure of Guideline Funding Source
Responsible, safe, and effective guidelines for 
patients on antithrombotic and anticoagulant therapy 
undergoing interventional techniques were commis-
sioned, prepared, edited, and endorsed by ASIPP with-
out external funding sought or obtained. 
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2.3.2 Disclosure and Management of Financial 
Conflicts of Interests
 Potential conflicts of interest for all panel mem-
bers within the last 5 years were evaluated prior to fi-
nalizing these guidelines. However, the panel members 
with potential conflicts were instructed by the panel 
and recused from related discussion or preparation of 
the guidelines and these members agreed not to discuss 
any aspect of the guideline with the industry before 
data publication. Further, conflicts of interests were in-
cluded based on interest confluence extending beyond 
financial relationships including personal experience, 
practice patterns, academic interests and promotions. 
2.3.3 Composition of the Guideline Development 
Group
A panel of experts, convened by ASIPP, reviewed 
the evidence and formulated recommendations for in-
terventional techniques in patients receiving antiplate-
let and anticoagulant therapy. The panel was instructed 
to assess the evidence pertaining to all important as-
pects of therapy and related complications. 
The panel provided a broad representation of 
academic and non-academic clinical practitioners with 
interest in interventional techniques in patients receiv-
ing antiplatelet and anticoagulant therapy. 
The panel composition was multidisciplinary in-
cluding methodologists (e.g., epidemiologists, statisti-
cians, and health services researchers) with experience 
in research and the conduct of systematic reviews. 
These members were voting members of the guideline 
development groups.
2.4 Evidence Review
Responsible, safe, and effective guidelines for 
patients on antithrombotic and anticoagulant therapy 
undergoing interventional techniques were developed 
utilizing evidence review, incorporating guidelines by 
other organizations and agencies, if available, and de-
veloping consensus among the panel members. 
The current guidelines offer recommendations 
based on scientific evidence and informed expert 
opinion. 
2.4.1 Grading or Rating the Quality or Strength of 
Evidence
This grading of evidence is based on randomized 
controlled trials (RCTs), observational studies, and 
other clinical reports based on availability. In addition, 
systematic reviews, meta-analyses, and evidence devel-
oped by other guidance are also given high importance 
with critical analysis. The recommendations have been 
developed using principles of best evidence synthesis 
developed by the Cochrane Review, incorporating mul-
tiple guidelines modified by ASIPP as shown in Table 1 
(161).
 This methodology specifies a level of scientific 
evidence and offers a transparent approach to grading 
quality of evidence and strength of recommendations. 
AHRQ also has recommended a similar strength of rec-
ommendation as shown in Table 2 (159,160). 
2.4.2 Assessment and Recommendations of 
Benefits and Harms
These guidelines intend to clearly describe the 
potential benefits and harms and explicitly link the 
information to specific recommendations.
2.4.3 Evidence Summary of Recommendations
Guideline supporting documents summarize the 
relevant supporting evidence and explicitly link this 
information to recommendations.
2.4.4 Rating or Grading the Strength of 
Recommendations
IOM standards demand that for each recommenda-
Table 1. Qualitative modified approach to grading of  evidence.
Level I Strong Evidence obtained from multiple relevant high quality randomized controlled trials for effectiveness 
Level II Moderate Evidence obtained from at least one relevant high quality randomized controlled trial or multiple relevant moderate or low quality randomized controlled trials
Level III Fair Evidence obtained from at least one relevant high quality nonrandomized trial or observational study with multiple moderate or low quality observational studies 
Level IV Limited Evidence obtained from multiple moderate or low quality relevant observational studies 
Level V Consensus based Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to assess preventive measures, adverse consequences, effectiveness of other measures.
Modified from: Manchikanti et al. A modified approach to grading of evidence. Pain Physician 2014; 17:E319-E325 (161).
Pain Physician: Guidelines Issue 2019; 22:S75-S128
S80  www.painphysicianjournal.com
tion, a rating of the strength of the recommendation 
related to benefits and harms, available evidence, and 
the confidence in the underlying evidence should be 
provided (158). 
2.4.5 Specificity of Recommendations
Guideline recommendations in this manuscript 
may not be very specific and occasionally may be am-
biguous, on what actions should or should not be taken 
in various situations of antithrombotic and antico-
agulant therapy during performance of interventional 
techniques due to the lack of extensive literature and 
discordant opinions.
2.5 Evidence Synthesis and Analysis
This comprehensive review was performed with ap-
propriate literature review and assessment. Due to the 
complexity of the subject and lack of systematic assess-
ment of bleeding complications and epidural hematomas 
in the literature, a systematic review and meta-analysis 
of RCTs and/or observational studies may not be feasible 
(158,162-164). Consequently, these guidelines focus on 
the available literature in reference to epidemiologic 
studies, observational reports, and case reports. Further, 
appropriate methods of data extraction and methodo-
logic quality assessment will be applied.
2.5.1 Data Sources 
The literature search was strategized based on 
multiple available sources including PubMed, the Co-
chrane library, Google searches, the U.S. Food and Drug 
Administration (FDA), the Centers for Disease Control 
and Prevention (CDC), and controlled clinical trials. The 
search was conducted over a time frame spanning from 
1966 to August 2018.
2.5.2 Search Strategy
The search strategy focused on antithrombotics, 
anticoagulants, antiplatelet agents, thrombotic events, 
cardiovascular events, cerebrovascular events, interven-
tional techniques, bleeding complications, and epidural 
hematoma following interventional techniques. 
2.5.3 Study Selection
The review focused on all types of reports and in-
cludes case reports and reviews. 
• Abstracts were screened in an unblinded standard-
ized manner by 2 review authors for all identified 
studies.
• Full text for all articles with relevance to the topic 
was retrieved for comprehensive review.
2.5.4 Data Extraction and Methodological Quality 
Assessment
Data extraction and methodologic quality assess-
ment was performed by at least two of the review 
authors independently, in an unblinded standardized 
manner. The quality assessment of each individual article 
used in this analysis was performed by utilizing the Co-
chrane review criteria (Appendix Table 1) (165), Interven-
tional Pain Management techniques Quality Appraisal of 
Reliability and Risk of Bias Assessment (IPM-QRB) criteria 
(Appendix Table 2) (166) for RCTs, and Interventional 
Pain Management Techniques – Quality Appraisal of Re-
liability and Risk of Bias Assessment for Nonrandomized 
Studies (IPM-QRBNR) (Appendix Table 3) (167). Utilizing 
the Cochrane review criteria (165) or IPM-QRB criteria 
(166), or IPM-QRBNR (167), studies meeting the inclusion 
criteria with a score of at least 9 to 13 for the Cochrane 
review criteria or 32 to 48 for the IPM-QRB and IPM-
QRBNR criteria were considered high quality; while 5 to 
Table 2. Guide for strength of  recommendations.
Rating for Strength of  Recommendation
Strong
There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true 
net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns 
about study quality; and/or d) the extent the panelists’ agreement. Other compelling considerations (discussed in the 
guideline’s literature review and analyses) may also warrant a strong recommendation.
Moderate
There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for a 
true net effect (e.g. benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few 
concerns about study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations (discussed 
in the guideline’s literature review and analyses) may also warrant a moderate recommendation. 
Weak
There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) 
limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; 
c) concerns about study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the 
guideline’s literature review and analyses) may also warrant a weak recommendation. 
Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (159).
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8 or 16 to 31 were considered moderate quality; whereas 
those with scores of less than 5 or 16 were considered 
low quality. Due to the scarcity of the literature, all stud-
ies were included in data synthesis or analysis. 
All systematic reviews, non-systematic reviews, all 
types of studies, and case reports were reviewed by 2 
authors. Any disagreements between the reviewers 
were resolved by a third author and consensus. If there 
were any conflicts of interest with a manuscript (i.e., 
authorship) the review authors were recused from as-
sessment and analysis. 
2.5.5 Analysis of Evidence
The analysis of the evidence was performed based 
on best-evidence synthesis and was modified and col-
lated using multiple available criteria, including the Co-
chrane Review criteria and the United States Preventive 
Task Force (USPSTF) criteria as illustrated in Table 1 (161). 
The analysis was conducted using 5 levels of evidence 
ranging from strong to opinion- or consensus-based. The 
results of best evidence as per grading were utilized. At 
least 2 of the review authors independently, in an un-
blinded, standardized manner, analyzed the evidence. 
Any disagreements between reviewers were resolved by 
a third author and consensus was attained. If there were 
any conflicts of interest (e.g., authorship), the reviewers 
of interest were recused from assessment and analysis.
2.5.6 Meta-analysis
The meta-analysis was planned to be performed 
using the Comprehensive Meta-analysis version 3.0 
(Biostat Inc., Englewood, NJ). Heterogeneity will be 
interpreted through I2 statistic. 
Random-effects model (single-arm) meta-analysis 
was planned to assess net changes in the same outcome 
variable (168-170). Heterogeneity among the effect 
sizes of individual studies will be assessed using the I2 
index and Q statistic. Heterogeneity analyzed with the 
I2 statistic was defined as low (25%–50%), moderate 
(50%–75%), or high (>75%). 
All analyses were based on if antithrombotics or 
anticoagulants were utilized or stopped. Meta-analysis 
was performed only when at least 3 studies were avail-
able and included an appropriate sample size of at least 
10 for nonrandomized studies.
2.6 External Review 
Guidelines have been subjected to external peer 
review as per the policies of the publishing journal, 
Pain Physician. 
2.7 Updating Guidelines
The responsible, safe, and effective guidelines for 
patients on antithrombotic and anticoagulant therapy 
undergoing interventional techniques will be updated 
in a window of 5 years, based on significant changes 
in the evidence, public policy, or adverse events before 
January 2024. 
3.0 results 
Our search strategy utilizing the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram as shown in Fig. 1, illustrated 
published literature evaluating interventional tech-
niques performed with or without antithrombotic and 
anticoagulant therapy. We identified multiple system-
atic reviews and guidelines (1,20,28,36,37,39,40,82,171-
174) and multiple individual manuscripts which met the 
criteria for inclusion (175-212). Due to very few studies 
with persistent high variability, conventional meta-
analysis or single-arm meta-analysis was feasible. 
3.1 Reviews and Guidelines
Among the 12 manuscripts describing guidelines 
and reviews, 2 manuscripts were related to ASIPP guide-
lines (1,82). The present guidelines are based on these 
guidelines published in 2013. Other guidelines of high 
importance are of the ones published by the ASRA (40). 
These guidelines have provided extensive descriptions 
with comprehensive review of the literature; however, 
these have been considered as more aggressive about 
stopping the antithrombotics than other available lit-
erature (36). Nevertheless, these are commonly utilized 
guidelines in the United States. Multiple other manu-
scripts include the guidelines from across the globe and 
reviews. A review by Oprea et al (20) described risk strati-
fication, perioperative and periprocedural management 
of the patient receiving anticoagulant therapy.
In addition, there were also guidelines related 
to the Neurostimulation Appropriateness Consensus 
Committee with recommendations on bleeding and 
coagulation management in neurostimulation devices 
(39). The guidelines from ASRA (40) and guidelines for 
neuromodulation procedures (39) stratified procedures 
into various risk categories. The guidelines by ASRA 
were revised which was prompted by reports of percu-
taneous lead placement with development of epidural 
hematoma in patients on aspirin. Prior to these recom-
mendations, low dose aspirin was considered as safe 
and was not stopped during interventional techniques 
including spinal cord stimulation.
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Breivik et al (36) provided a comprehensive review 
of reducing the risk of spinal hematoma from spinal 
and epidural pain procedures. They provided recom-
mendations for interventional techniques with updated 
guidance.
In addition, in a quasi-systematic review assessing 
the risks and benefits of ceasing or continuing antico-
agulant medication for image-guided procedures for 
spine pain (33), the authors evaluated 14 manuscripts 
which provided applicable evidence. The results showed 
Fig. 1. Flow diagram illustrating published literature evaluating interventional techniques performed with or without 
antithrombotic and anticoagulant therapy.
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procedures involving interlaminar access carried a non-
zero risk of hemorrhagic complications, regardless of 
whether anticoagulants were ceased or continued. For 
other procedures, hemorrhagic complications have not 
been reported, and case series indicated that they are 
safe when performed in patients who continue antico-
agulants. The results of this review identified reports 
of adverse effects of ceasing anticoagulants, with seri-
ous consequences, including death. The authors of this 
manuscript concluded that other than for interlaminar 
procedures, the evidence does not support the view 
that anticoagulant and antiplatelet medication must 
be ceased before image-guided spine pain procedures.
3.2 Prevalence and Risk Assessment of Studies
Multiple studies have been published assessing the 
prevalence, as well as the risk of bleeding with inter-
ventional techniques (31-34,37,41,42,50-54). 
In a survey of practice patterns among interven-
tional pain physicians in 2012, Manchikanti et al (31) 
showed that the majority of physicians discontinued 
antithrombotic agents; however, this study also showed 
that there were a significantly higher number of com-
plications related to thromboembolic events of a total 
of 162 compared to hemorrhagic complications of a 
total of 55 in this population. 
In a prospective evaluation of bleeding risks for 
interventional techniques in chronic pain, Manchikanti 
et al (32) assessed the rates of adverse events in patients 
undergoing interventional techniques on antithrom-
botic therapy with cessation or without cessation and 
compared them to a group of patients without anti-
thrombotic therapy. While the results showed differ-
ences in milder complications, there were no reports of 
hemorrhagic complications requiring any type of treat-
ment. In this assessment, the authors studied all types 
of procedures with 1,227 of 1,831 continuing aspirin 
compared to 604 of 1,831 discontinuing them. Simi-
larly, they also studied 100 patients on clopidogrel with 
continuation, whereas, 226 patients were discontinued. 
Further, there were 128 patients with aspirin and other 
agents with continuation and 151 were discontinued. 
The procedures performed included cervical epidural 
injections with continued aspirin in 249 patients, tho-
racic epidural in 30 patients, lumbar interlaminar 
epidural in 128 patients, lumbar transforaminal in 144 
patients, whereas 528 patients for caudal epidural in-
jections, and 148 for percutaneous adhesiolysis. In ref-
erence to clopidogrel, it was continued in 10 patients 
undergoing cervical epidural, one patient with thoracic 
epidural, 14 patients with lumbar epidural, 44 patients 
with caudal epidurals, 10 with lumbar transforaminal 
epidural, and 21 with percutaneous adhesiolysis. There 
were a large number of facet joint interventions and 
other treatments. 
van Helmond et al (51), in a retrospective review, 
assessed the safety of low to intermediate risk spine 
procedures in patients with continued antithrombotic 
therapy. They identified 490 patients of a total of 2,204 
patients on antithrombotic medications which included 
aspirin (N=275), P2Y12 inhibitors (N = 129), warfarin (N 
= 62), heparin (N = 10), factor Xa inhibitors (N = 55), and 
dipyridamole (N = 1). The procedures included facet 
joint nerve blocks and facet joint radiofrequency in all 
3 regions and sacroiliac joint injections. The authors 
concluded that there were no hemorrhagic complica-
tions in performing these procedures. 
Goodman et al (50) studied the role of antico-
agulant and antiplatelet management for spinal pro-
cedures in a prospective descriptive study. Out of 4,253 
procedures, 197 of them were performed in 74 patients 
on antiplatelet/anticoagulants, they reported no clini-
cally evident bleeding events for lumbar transforaminal 
epidural injections (N=90), facet joint injections (N=62), 
lumbar intradiscal procedures (N=11), lumbar sympa-
thetic blocks (N=3), sacroiliac injections (N=5), or in 26 
radiofrequency neurotomy procedures. However, simi-
lar to van Helmond et al (51), Goodman et al (50) have 
not performed any epidural injections on patients with 
continuation of antiplatelet therapy. 
Endres et al (42) assessed risks of continuing or 
discontinuing anticoagulants for patients undergoing 
interventional procedures. They reported no compli-
cations attributable to anticoagulants in 4,766 proce-
dures in which anticoagulants were continued. They 
mainly performed lumbar transforaminal injections, 
lumbar medial branch blocks, trigger point injections, 
and sacroiliac joint blocks, and they concluded that 
continuation of anticoagulant therapy seems to be 
safe. They performed interlaminar epidural injections 
in 25 patients with continuation of Warfarin and 15 
patients with continuation of clopidogrel. In addition, 
they reported 171 patients undergoing sacroiliac joint 
blocks on Warfarin, 227 patients undergoing trigger 
point injections, 40 patients with trochanteric bursa in-
jections, and 87 patients with hip joint injections, they 
also reported 81 patients with clopidogrel undergoing 
sacroiliac joint blocks, 214 patients with trigger point 
injections, 50 patients with trochanteric bursa injec-
tions, and 52 patients with hip joint injections. 
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Warner et al (54) in a manuscript describing bleed-
ing and neurological complications in 58,000 inter-
ventional pain procedures showed that preprocedural 
aspirin or nonsteroidal antiinflammatory drug therapy 
was prevalent in 17,825 procedures or 30.7% of the 
procedures without significant bleeding complica-
tions. Out of total 58,066 procedure performed in the 
study; 22.4% of the procedures were performed with 
perioperative administration of aspirin within 7 days, 
12.1% of the patients with administration of nonste-
roidal anti-inflammatory drugs within 7 days, 1.6% of 
clopidogrel within 7 days. The study also included 3,880 
lumbar epidural injections, 304 thoracic interlaminar in-
jections with a large number of epidural injections with 
over 50% of the epidural injections not assigned to a 
region. They concluded that bleeding complications 
were rare in patients undergoing low or intermediate 
risk pain procedures even in the presence of antiplate-
let medication. 
Lagerkranser (52) and Lagerkranser and Lindquist 
(53) have published extensive review of neuraxial blocks 
and spinal hematoma in 2 parts from 1994 to 2015 cov-
ering demographics, risk factors, diagnosis, treatment, 
and outcome. They also considered previous reviews 
published in 1992 (175), 1994 (176), and 1996 (177) case 
reviews, analyzing 29, 61, and 51 cases of spinal hema-
toma after neuraxial blocks, respectively, between 1906 
and 1996. They identified multiple changes in the peri-
operative management of surgical patients, thrombo-
prophylaxis with multiple newer agents, and multiple 
published guidelines. They identified 147 published 
articles, case reports or letters, describing altogether 
166 cases relevant for the review. They showed that 64 
cases were from Europe, 53 from North America, 4 from 
South America, 39 from Asia and 6 from Australia. They 
reported hematoma formation secondary to multiple 
types of neuraxial blocks, including spinal injections, 
epidural injections, combined spinal and epidural 
injections, and spinal cord stimulators. They reported 
49 lumbar injections with 12 single shots, 46 thoracic 
injections all with continuous and 6 cervical locations 
with 5 single shots secondary to epidural injections. A 
large number of hematomas appeared after removal of 
the catheter. In managing chronic pain with epidural 
injections, they identified 21 hematomas, 17 (5 cervical, 
4 thoracic, and 8 lumbar) after epidural injections, and 
4 after percutaneous application of spinal cord stimula-
tors. However, they have not identified the number of 
patients developing hematoma with appropriate cessa-
tion of antithrombotic therapy based on recommended 
guidelines. Overall, they showed that 37% of the pa-
tients who were not on antihemostatic drugs, whereas 
63% were on antihemostatic drugs with 47 of the cases, 
receiving more than one antihemostatic drug, and 12 
receiving 3 such drugs. Further, they also had 6 reports 
which were indeterminate. Consequently, the number 
of patients without antithrombotic therapy, but with 
hematoma formation seems to be almost 40%. 
Lagerkranser (52) showed that an annual aver-
age of 7.5 published cases of spinal hematoma in the 
years 1994 to 2015, compared to an average of only 
2.5 case reports per year from 1976 to 1993 (176). They 
also identified that there has been a transition from a 
male to female dominance among patients suffering 
from post-neuraxial blockade and spinal hematoma 
particularly among the elderly women. In addition, 
guidelines issued around the turn of the century have 
not been followed by a reduced number of published 
case reports, even though adherence to the guidelines 
has increased during the last decade. 
The authors identified spinal stenosis as the most 
common spinal disease in 14 cases with spinal disease 
reported in 37 cases of 166 cases (52). They identified 
bloody tap at the introduction of a neuraxial needle or 
catheter as a major risk factor, but multiple attempts to 
reach the spinal canal do not seem to increase the risk 
of spinal hematoma. Their results also showed that 80% 
of the patients developing spinal hematoma had severe 
neurological symptoms with paresis or paralysis. When 
compared over time, outcomes have improved sig-
nificantly (52). The results showed that among patients 
subjected to surgical evacuation of the hematoma, 
outcomes were best if surgery was performed within 
12 hours from the first sign of motor dysfunction. How-
ever, even patients operated after more than 24 hours 
had relatively favorable outcomes. Further, outcomes 
after surgical evacuation of the epidural hematoma 
were satisfactory, compared to subdural hematoma, 
which had poor outcomes. They recommended that 
suspicion of spinal hematoma calls for the consultation 
of surgeon without delay. Magnetic resonance imaging 
(MRI) was the recommended diagnostic tool. Surgical 
evacuation within 12 hours from the sign of motor 
dysfunction seems to lead to the best outcome, even 
though many patients operated as late as after more 
than 24 hours did regain full motor function (52).
Moeschler et al (34) assessed bleeding complica-
tions in patients undergoing percutaneous spinal cord 
stimulator trials and implantations with retrospective 
review from 2005 through 2014 of all patients, with as-
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sessment of 642 percutaneous spinal cord procedures, 
346 spinal cord stimulator trials, 255 spinal cord stimu-
lation implantations, and 41 revision surgeries. Patients 
had received aspirin or NSAIDs within 7 days of needle 
placement for 101 procedures (15.7%). There were no 
bleeding or neurological complications identified in 
this cohort. Consequently, this study showed that there 
were no risks associated with patients receiving aspirin 
or other NSAIDs within 7 days of needle placement in 
approximately 16% or 100 procedures; however, they 
warned that further investigations with larger numbers 
are needed to better define the relationship between 
periprocedural aspirin and NSAID utilization and bleed-
ing complications. 
Petraglia et al (41) also studied the incidence of 
spinal cord injury in implantation of percutaneous and 
paddle electrodes for spinal cord stimulation, with 
analysis of nationwide data, with inclusion of 8,326 
patients. They showed overall incidence of spinal cord 
injury of 2.1%, with incidence of spinal hematoma of 
0.71%, which was seen in 59 patients with 41 in per-
cutaneous group with 0.75% and 18 in paddle lead 
group with 0.63%. They concluded that while revers-
ible complications may be more common, spinal cord 
injury as a result of spinal cord stimulation is uncom-
mon. Even though this was a large database, they rec-
ommended for more studies to further characterize the 
mechanisms of injury and outcomes in these patients. 
They also assessed odds ratio for using antiplatelet or 
anticoagulant medications within 30 days prior to spi-
nal cord stimulation procedures. They found that the 
odds of spinal cord injury increased by 2.4. If the patient 
took any type of anticoagulant medication within 30 
days prior to the procedure they found no significant 
increase in the odds of spinal cord injury for patients 
taking aspirin, clopidogrel, or enoxaparin alone. 
LaVallee et al (35) studied the prevalence of bleed-
ing complications following ultrasound-guided botu-
linum toxin injections in patients on anticoagulation 
or antiplatelet therapy. They reviewed 328 ultrasound 
guided intramuscular procedures performed in 15 pa-
tients with the predominant indication for chemode-
nervation being spastic paresis secondary to stroke. Of 
328 procedures, only 2 subclinical hematomas were 
detected, resulting in a bleeding complication rate of 
0.61% in this patient population. 
Table 3 describes the studies assessing the risk of 
thrombosis and bleeding with interventional pain 
management techniques. All but 2 studies in this assess-
ment are related to performing interventional tech-
niques without cessation of antithrombotic therapy 
(30-34,37,39,41,42,50,51). Only 2 studies (31,52) were 
related to an online physician survey and study of spinal 
hematoma with neuraxial blocks. Among all the stud-
ies, only 2 studies included epidural injections (32,42). 
All others have performed a large proportion of pro-
cedures with low risk or intermediate risk including 
transforaminal epidural injections. As shown in Table 4, 
interlaminar procedures were performed to a large ex-
tent by Manchikanti et al (32) with inclusion of patients 
undergoing cervical epidural, thoracic epidural, lumbar 
epidural, caudal percutaneous adhesiolysis with aspirin, 
warfarin, clopidogrel, and aspirin plus other drugs. En-
dres et al (42) also studied lumbar interlaminar epidural 
injections in 25 patients with continuation of warfarin 
and 15 patients with continuation of clopidogrel and 2 
patients with continuation of cilostazol and enoxapa-
rin. Lagerkranser (52) also reported 37% of the patients 
who were not on antithrombotics. 
Based on the evidence presented from these stud-
ies, it appears that there is no significant difference 
whether antithrombotic therapy is discontinued or 
continued in reference to the bleeding. A majority of 
the authors have studied intermediate and low risk 
procedures without the inclusion of epidural injections. 
The only one study reviewing spinal cord stimulation 
also showed lack of increased risk with continuation of 
aspirin and other NSAIDs.
3.3 Reports of Thromboembolic Events
There have been multiple reports of thromboem-
bolic events with discontinuation of antithrombotics 
and anticoagulants prior to performance of interven-
tional procedures. Manchikanti et al (31) in assessment 
of practice patterns of perioperative management of 
antiplatelet and anticoagulant therapy in interven-
tional pain management reported 162 thromboembolic 
events compared to 55 serious bleeding complications 
from epidural hematomas. This study showed thrombo-
embolic events were 3 times more frequent than bleed-
ing complications. Further, they also showed bleeding 
complications from epidural hematomas were similar 
whether antiplatelet therapy was continued or discon-
tinued with an occurrence of 26 versus 29 respectively; 
in this survey the sample sizes were not provided. Con-
sequently, it is difficult to assess exact risk of bleeding 
complications and similarly thromboembolic events.
Endres et al (42) reported 9 patients with thrombo-
embolic events after cessation of anticoagulant therapy 
of 1,626 procedures. These complications included 2 
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deaths 5 strokes, one pulmonary embolism, and one 
myocardial infarction in patients when anticoagulants 
were stopped; however, they have not reported any 
bleeding complications in patients where antico-
agulants were continued, although, with inclusion of a 
small number of epidural injections with high risk. Ku-
mar et al (178) reported a case of pulmonary embolism 
after discontinuation of warfarin during spinal cord 
stimulation trial. Linn et al (179) also reported right 
middle cerebral artery infarction with persistent left 
hemiparesis, neglect and dysarthria with L5-S1 epidural 
steroid injection after discontinuation of warfarin for 9 
days preprocedure. Manchikanti et al (138) in providing 
2 case reports and literature review described 2 cases 
of thromboembolic complications with cessation of 
antithrombotic therapy. Table 5 shows reported throm-
boembolic and cardiovascular complications related 
to discontinuation of antiplatelet or anticoagulation 
therapy.
3.4 Case Reports of Bleeding Complications
There were 35 case reports discovered citing epi-
dural hematoma in patients with or without continued 
antithrombotic therapy during an interventional tech-
nique (130-138,148,180-204). 
Table 6 shows reports of bleeding and epi-
dural hematoma associated with interventional 
techniques in patients without antithrombotic ther-
apy (136,138,140,144,180,183,185,190,192-195,197, 
201,203,204,206,208,209), whereas Table 7 shows reports 
of bleeding in patients with discontinued antithrombot-
ic therapy (130,133-135,138,139,148,181,187-189,191). 
Table 8 shows reports of bleeding complica-
tions and epidural hematoma in patients with 
continuation of antiplatelet therapy with interven-
tional techniques. Multiple reports of bleeding com-
plications with continuation of anticoagulant therapy 
during interventional techniques were identified 
(131-133,136,137,182,199,200,202). 
Table 4. Interlaminar epidural procedures with continuation or discontinuation of  antithrombotic therapy. 
Aspirin Warfarin Clopidogrel Aspirin + Others Cilostazol & Enoxaparin
D C T D C T D C T D C T D C T
Manchikanti et al (32)
Cervical Epidural 161 249 410 12 1 13 67 10 77 34 18 52 NA NA NA
Thoracic Epidural 19 30 49 1 1 2 7 1 8 NA 5 5 NA NA NA
Lumbar Epidural 63 128 191 23 NA 23 16 14 30 28 9 37 NA NA NA
Percutaneous Adhesiolysis 68 148 216 24 NA 24 16 21 37 37 32 69 NA NA NA
Epidurals - Total 311 555 866 60 2 62 106 46 152 99 64 163 NA NA NA
Endres et al (42)
Lumbar interlaminar NA NA NA 169 25 194 69 15 84 NA NA NA 0 2 2
Epidurals - Total 311 555 866 229 27 256 175 61 236 99 64 163 0 2 2
None = Not on antithrombotic drugs; D = discontinued; C = continued; T = total 
Others: Sacroiliac joint interventions, occipital nerve blocks, intercostal nerve blocks, stellate ganglion block, or lumbar sympathetic blocks
Table 5. Thromboembolic and cardiovascular complications related to discontinuation of  antiplatelet or anticoagulation therapy.
Study Type of  study Complications
Endres et al (42) Observational report of interventional 
techniques
•  2 patients died
•  5 suffered strokes
•  1 suffered pulmonary embolism
•  1 suffered myocardial infarction
Kumar et al (182) Case report of dorsal column stimulator 
trial
•  Pulmonary embolism without lasting complications
Linn et al (183) Case report of L5/S1 epidural steroid 
injection
•  Right middle cerebral artery infarction with persistent left 
hemiparesis, neglect, and dysarthria
Manchikanti et al (31) Online survey •  Reports of epidural hematoma: 55 
•  Reports of thromboembolic complications: 162
Manchikanti et al (138) Case report and literature review of 
interventional techniques
•  2 cases of thromboembolic complications with cessation of 
antithrombotic therapy.
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Table 6. Reports of  bleeding and epidural hematoma associated without antithrombotic therapy with interventional techniques.
Study/Year Case Report Conclusions 
Swicegood et al, 
2017 (136)
Authors reported a cervical epidural hematoma in a 41-year-old 
Caucasian female with controlled hypertension, but with no drug therapy 
contributing to bleeding. She received uneventful epidural injection and 
developed neurological dysfunction necessitating surgical decompression. 
She recovered without residual dysfunction.
Epidural hematoma developed in a patient without 
antithrombotic or anticoagulant therapy.     Authors 
described this case of epidural hematoma in a patient 
with no risk factors or anticoagulant or antiplatelet 
therapy.
Manchikanti et al, 
2017 (138)
Authors reported a case of 61-year-old female without risk factors or 
anticoagulant therapy. Epidural injection was performed in the cervical 
spine without difficulty. Patient developed symptomatology leading to the 
diagnosis of cervical epidural hematoma within 3 hours after the procedure 
undergoing surgical intervention due to progressive neurological 
dysfunction. 
Epidural hematoma occurred after required period 
to discontinue aspirin. This patient had no other risk 
factors or other anticoagulant therapy. Patient was 
also successfully managed conservatively without 
surgical intervention.    Patient developed epidural 
hematoma without any risk factors or anticoagulant 
therapy. 
Manchikanti et al, 
2018 (140)
Cervical epidural hematoma was reported in a healthy 43-year-old 
functioning female patient without overt risk factors for procedural 
hemorrhagic complications including baseline coagulopathy, baseline 
dysfunction, and intake of anticoagulants. There were no technical 
difficulties in performing the procedure.    Patient developed 
symptomatology leading to the diagnosis of cervical and thoracic epidural 
hematoma with progressive neurological dysfunction necessitating surgical 
decompression. 
Authors concluded that epidural hematoma may 
happen in cervical epidural injections considered 
as high risk procedure without antiplatelet or 
anticoagulant therapy and also without any risk 
factors.
Berrigan et al, 
2018 (144)
Cervical epidural hematoma was reported in a 62-year-old healthy female 
patient after dry needling in cervical and thoracic musculature. Patient 
developed neurological dysfunction leading to the diagnosis of cervical and 
thoracic epidural hematoma confirmed by MRI. Due to stable neurological 
function, surgical intervention was deferred. She was managed with 
conservative management without residual dysfunction.
Authors report an epidural hematoma with dry 
needling, which is considered as extremely unusual 
in a patient without risk factors or antiplatelet or 
anticoagulant therapy.
Desai & Dua, 
2014 (180)
This is a case report of a 72-year-old female undergoing right 
transforaminal epidural injection at L3 and L4.    Four days after the 
injection patient reported progressive right lower extremity weakness, 
worsening sensory loss, and ambulatory dysfunction.     An MRI with 
gadolinium enhancement showed focal abnormal signal with involvement 
of the right L4-5 neuroforamina that extended slightly far laterally, 
consistent with a small hematoma, affecting L4 nerve root.     There was no 
history of coagulopathy.
This case report shows that though extremely rare, 
perineural or foraminal hematoma may occur as 
a serious complication of transforaminal epidural 
injection, even in the setting of a standardized 
procedure.
Ghaly, 2001 (183) A 56-year old man who developed Brown-Séquard syndrome from a spinal 
epidural hematoma after fluoroscopically-guided cervical steroid injection. 
The patient reported immediate sharp shooting pain in the upper 
extremities on introduction of epidural Tuohy needle. Within half an hour, 
a neurological deficit occurred at C7/8 and right Brown-Séquard syndrome 
developed. MRI showed C6 to T2 spinal epidural hematoma with cord 
compression.     Emergency spinal bilateral decompressive laminectomies 
and evacuation of spinal hematoma were performed within an expected 
delay of 10 hours from the onset of neurological deficit from C6 to T12.
Patient developed epidural hematoma without any 
risk factors or anticoagulant therapy. 
Stoll & Sanchez, 
2002 (185)
A healthy 34-year old man with no evidence of coagulopathy and not 
taking antiplatelet medication suddenly had onset of acute cervical 
myelopathy from a large cervical epidural hematoma 8 days after cervical 
epidural steroid injection. The patient developed a Brown-Séquard type 
of myelopathy manifesting by severe weakness of the left arm and leg and 
right-sided numbness and loss of temperature appreciation. The diagnosis 
was made by CT scan. Following prompt surgical evaluation of the clot, the 
patient made a near complete recovery.
The authors concluded that this case illustrated 
that epidural hematoma may occur in the absence 
of known risk factors. The delayed onset and the 
absence of risk factors have implications for the 
use of epidural steroid injection in chronic pain 
management.
Lee et al, 2011 
(190)
A 58-year old woman presented with quadriparesis and neck pain after 
dry needling. MRI of the spine revealed a hyperintense mass in the T2 
weighted at C2-T2 level, which proved to be an epidural hematoma. The 
diagnosis was made with MRI and decompression was carried out. The 
patient recovered completely.     There were no risk factors and the patient 
was not on antiplatelet therapy.
The authors concluded the spinal hematoma caused 
by dry needling in this case was probably the result of 
unintentional needling of the spinal canal, similar to 
that caused by central neural blockade. 
Ozdemir et al, 
2007 (193)
Epidural steroid injection was performed with a #18 gauge Tuohy needle 
which revealed a dural puncture in a 40-year old male. The second attempt 
at L3/4 level was successful.     MRI showed a right frontal subdural 
hematoma. His headache was relieved after strict bedrest, intravenous 
hydration, and analgesics. The patient was discharged with full recovery 
after one week without neurological dysfunction.
The authors concluded that intracranial subdural 
hematoma for accidental dural puncture during 
epidural steroid injection is a rare complication, even 
though there were no risk factors in this patient.
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Table 6 (cont.). Reports of  bleeding and epidural hematoma associated without antithrombotic therapy with interventional techniques.
Study/Year Case Report Conclusions 
Lee et al, 2007 
(195)
A healthy 38-year-old woman underwent a series of right transforaminal 
epidural injections at the C7-T1 level. Approximately 4 days after the final 
injection, she awakened with severe upper thoracic pain and progressive 
loss of sensation in the lower extremities. MRI of the spine showed a large 
hematoma extending from T1 to T5.     The patient underwent surgical 
decompression. Within 6 months patient regained full strength and 
sensation in both lower extremities.
The authors cautioned that the physician should 
be aware that symptoms from a slowly developing 




A report of acute spinal epidural hematoma after acupuncture extending 
from C2 through T12. Due to rapid improvement with the patients’ 
neurological symptoms, conservative treatment was adopted with excellent 
long-term results.
Acupuncture may produce epidural hematoma.
Keane et al, 1993 
(201)
A case report of a 65-year-old female with development of epidural 
hematoma at T5-T6 several hours after acupuncture.    Conservative 
management resulted in complete recovery.
Acupuncture may produce epidural hematoma.
Kim & Park, 2015 
(203)
A 39-year-old female underwent cervical epidural injection at C6 under 
fluoroscopic guidance.     Five days after epidural injection she complained 
of mild headache that was increasing in the upright position with a normal 
CT scan. At this time, she was treated with conservative management for 
post dural puncture headache.     One month later, she presented with 
a severe headache that was not relieved by analgesic medication, which 
changed in character from being positional to non-positional during the 
preceding month.     Brain magnetic resonance imaging revealed a chronic 
subdural hematoma along the left convexity.    Emergency Burr Hole 
drainage was performed and the headache abated.
This report indicated that an intracranial chronic 
subdural hematoma presenting with intractable 
headache after cervical epidural steroid injection 
should be considered a possible complication. In 
addition, the event of an intractable and changing 
post dural puncture headache after epidural injection 
suggests further evaluation for diagnosis of an 
intracranial hematoma.
Takawira et al, 
2012 (204)
A 52-year old male patient underwent spinal cord trial stimulation 
placement from T8 through T10 levels bilaterally with epidural entry at 
T12 and L1 interspace. 72 hours after the placement with good pain relief, 
he suddenly noticed relocation of stimulation to his right flank, with 
an abrupt onset of 10/10 burning lower back pain radiating down both 
lateral thighs and accompanied by inability to lift his knees. The patient 
also exhibited neurological deficits and loss of rectal tone.    The trial leads 
were immediately removed and an MRI was performed. This showed 
an epidural or subdural fluid collection surrounding and compressing 
the thecal sac and spinal cord, extending from C7 to L3, which was 
interpreted as possibly a rapidly developing epidural hematoma. The 
epidural hematoma was a “thin spread” which was postulated as secondary 
to dislocation of the lead rather than trauma of the insertion.     Epidural 
hematoma resolved rapidly and no surgical intervention was required with 
full recovery. 
This is another case of spinal cord trial stimulation 
causing epidural hematoma with full recovery, but 
may cause severe problems. The authors noted 
that based on the retrospective analysis using a 
Manufacturer and User Facility Device Experience 
(MAUDE) database, the incidence of epidural 
hematoma was about 0.19%.
Smith et al, 2010 
(206)
The authors reported 2 cases of epidural hematoma out of 4 complications 
related to spinal cord stimulations admitted to an acute spinal cord 
rehabilitation hospital over a 4-month period.     The first patient with 
hematoma after placement of stimulator trial leads developed acute new 
mid back pain associated with rapid progressive weakness and motor 
loss to his bilateral lower extremities on day 5 associated with urinary 
retention. The pattern of weakness began in the right lower extremity and 
then progressed to the left lower extremity.    A thoracic CT myelogram 
and CT of the thoracic spine with intrathecal contrast showed an epidural 
hematoma which extended 2 levels above the area of the spinal cord 
stimulator placement. The patient was not on any anticoagulants and all 
the studies were normal.     On postoperative day 5, the patient underwent 
a thoracic T8/9 laminectomy with excision of epidural hematoma and 
removal of spinal cord stimulator electrodes. The patient developed 
permanent spinal cord injury
  Spinal cord hematoma developing after a trial 
without any risk factors. Recovery was poor after 
acute rehabilitation.
Smith et al, 2010 
(206)
The authors reported 2 cases of epidural hematoma out of 4 complications 
related to spinal cord stimulations admitted to an acute spinal cord 
rehabilitation hospital over a 4-month period.    The authors reported a 
second patient, a 66-year old female with a history of chronic low back 
pain with stimulator leads placed in a patient with moderate to severe canal 
stenosis at L1/2 and L2/3 with epidural hematoma and air spanning T9-
L2/3 and mass effect increasing the canal narrowing of the L1/2 and L2/3 
levels.     She underwent decompressive thoracic and lumbar laminectomies 
of T11-L2 levels. After acute inpatient rehabilitation stay, she recovered 
full motor strength in bilateral lower extremities. However, she was 
independent with limited community ambulation and had full bladder and 
bowel function recovery. She was diagnosed with spinal cord injury at T7.
Spinal cord hematoma developing after trial in a 
patient with severe spinal stenosis; however, without 
any antithrombotic therapy with moderate recovery 
after acute rehabilitation.
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Table 6 (cont.). Reports of  bleeding and epidural hematoma associated without antithrombotic therapy with interventional techniques.
Study/Year Case Report Conclusions 
Chen et al, 1997 
(208)
A case of a 48-year-old female developing epidural hematoma one week 
after acupuncture at L1-2. Patient was managed conservatively with 
complete recovery.
Acupuncture may produce epidural hematoma.
Eftekhar et al, 
2005 (192)
A 74-year-old male patient developed epidural hematoma 2 days after 
acupuncture at L2-3.    Patient underwent laminectomy with complete 
recovery.
Acupuncture may produce epidural hematoma.
Chen et al, 2006 
(194)
A 30-year-old male patient with upper back pain developed epidural 
hematoma from C7-T3 one hour after acupuncture.     Patient underwent 
laminectomy with complete recovery.
Acupuncture may produce epidural hematoma.
Nam et al, 2010 
(209)
A 60-year-old male patient with back pain developed epidural hematoma 
5 days after acupuncture from L4-S1.     Patient underwent laminectomy 
with complete recovery.
Acupuncture may produce epidural hematoma.
Table 7. Reports of  bleeding and epidural hematoma in patients after discontinuation of  antithrombotic therapy after interventional 
techniques.








Clopidogrel 12 days Acute epidural hematoma formation was reported in cervical 
spine after interlaminar epidural steroid injection despite 
discontinuation of clopidogrel for 12 days.    Procedure 
was performed atraumatically between C7 and T1 under 
fluoroscopic guidance and contrast injection. The patient 
started complaining of severe pain immediately after transfer 
to the recovery area. The patient underwent an expedited 
cervical spine MRI identifying a large epidural hematoma 
which was surgically decompressed with full recovery.    
Patient was given 30 mg of ketorolac intramuscularly for pain.
Epidural hematoma occurred 
in a patient after stopping of 
clopidogrel 12 days prior to 
the procedure.    Ketorolac 
may contribute to exacerbation 
of hematoma. However, the 
patient was already significantly 
symptomatic prior to 
administration of ketorolac.
Giberson et al 
(133)
Low dose aspirin 
81 mg and other 
NSAIDs
One week This is a case report of a 70-year old patient undergoing 
spinal cord stimulator trial lead placement. He discontinued 
low dose aspirin 81 mg and other NSAIDs one week before 
the trial.     After the removal of the trial after 4 days, the 
patient developed acute onset of burning lower thoracic pain 
and lower extremity weakness and spasms. An emergent 
MRI image revealed epidural hematoma extending from 
T8 to L3 with significant cord compression.    The patient 
underwent an emergent T8 to T11 laminectomy and 
evacuation of the hematoma. He had complete resolution of 
his symptoms and was discharged home in good condition.
The authors reported, along 
with this case, another case 
where the patient took aspirin 
the day of the removal of the 
leads and developed hematoma.     
Consequently, they concluded 
aspirin must be discontinued. 
However, it is puzzling that this 
patient was on aspirin; however, 
he discontinued 7 days prior to 
the procedure. 







This case report involves a 67-year old woman undergoing 
interlaminar epidural injection with significant spinal stenosis 
at multiple levels undergoing interlaminar epidural injection 
with an #18 gauge Tuohy needle utilizing a paramedian 
approach with a single attempt.    The patient developed 
weakness in legs the next day, 18 hours after the procedure. 
She had minimal relief with pain after the procedure. That 
evening around 11:30 pm, she was taken to the emergency 
room with weakness and inability to completely empty the 
bladder with an emergent MRI, which showed epidural 
hematoma from L3 to L5 with significant compression of the 
cauda equina.    The patient underwent laminectomy within 
4 hours of arrival to the emergency room. Total time from 
injection to the operating room was approximately 35 hours. 
She developed a permanent foot drop.
The authors described presence 
of spinal stenosis and the 
interlaminar approach seem to 
be significant risk factors in this 
patient. The epidural hematoma 
developed despite discontinuation 




Aspirin, 81 mg 7 days Authors reported a thoracic epidural hematoma after 
interlaminar epidural injection in a patient on 81 mg 
aspirin therapy which was discontinued 7 days prior.    
Epidural injection was performed at T10-11 leading to 
symptomatology developing of neurological dysfunction 
within 2 hours. Surgical decompression was carried out with 
rapid recovery.
Epidural hematoma developed 
despite stopping low dose aspirin 
81 mg within the required time 
of 7 days.
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Aspirin 9 days A case of cervical epidural hematoma in a 68-year-old 
Caucasian female patient was presented. Patient was on 81 
mg of aspirin which was discontinued 9 days prior to the 
procedure. Following an uneventful cervical interlaminar 
epidural injection she developed symptomology with the 
diagnosis leading to epidural hematoma confirmed by 
MRI. She was managed conservatively with improving 
symptomatology and recovered completely.
Epidural hematoma occurred 
after required period to 
discontinue aspirin. This patient 
had no other risk factors or other 
anticoagulant therapy. Patient 
was also successfully managed 
conservatively without surgical 
intervention.





7 days Authors reported a lumbar epidural hematoma with late 
onset, 3 weeks after the performance of epidural steroid 
injection in a patient with spinal stenosis at L4-5 interspace. 
Patient was on clopidogrel, aspirin, and beraprost following 
infrarenal abdominal aortic aneurysm repair. Clopidogrel 
and aspirin were stopped 7 days prior to the epidural 
injection. Symptomatology developed 3 weeks after the 
epidural injection with formation of a large hematoma to 
cause severe thecal compression.    Patient was managed 
conservatively without residual complications.
Epidural hematoma with late 
onset 3 weeks after the procedure 
in a patient after withholding 
appropriately clopidogrel and 
aspirin for 7 days.    The authors 
also identified spinal stenosis as a 
contributing risk factor.
Caputo et al 
(148)
Dabigatran 7 days A 70-year old patient underwent lumbar interlaminar 
epidural injection under CT guidance at L4/5.     Dabigatran 
was started 24 hours after the injection. The patient had 
complete resolution of the symptoms.     48 hours after the 
injection, the patient started developing numbness in both 
lower extremities and had nearly complete paraplegia of the 
bilateral lower extremities. An emergent MRI showed an 
acute stenotic lesion, which was not present on the previous 
MRI. The patient was immediately decompressed. The 
patient was treated with multiple units of packed red blood 
cells prior to decompression. On surgical exposure, there 
was a large hematoma from L3-L5. Surgical evacuation of the 
hematoma was carried out with full neurological recovery 6 
months after surgery. 
The authors concluded that 
there is no reversal protocol 
for dabigatran. Dabigatran was 
stopped 7 days prior, which 
is longer than recommended 
duration. However, it was started 
one day after the procedure, 
which seems to have resulted in 
hematoma formation.
Shanthanna 
& Park et al 
(181)
Warfarin Stopped for 
4 days with 
an INR of 1.2 
on the day 
of epidural 
injection
A 65-year-old male patient was treated with lumbar epidural 
injection at L3-4 in the sitting position with a second attempt 
which was atraumatic.     Patient reported severe back 
pain and inability to stand 20 minutes after the procedure. 
An MRI scan performed within 3 hours of the patient’s 
symptomatology revealed a localized dorsal/lateral thoracic 
epidural hematoma at T10 to T12.    After neurosurgical 
referral, conservative management was provided with 
significant improvement within a day without having 
sustained any neurological deficit. An MRI done at the 
follow-up visit, a week later, showed a resolving hematoma.
Epidural hematoma developed 
after appropriate discontinuation 
of Warfarin and ideal INR of 
1.2 within 20 minutes after the 
epidural injection. Epidural 
injection was at L3-4 level; 
however, hematoma was at T10 to 
T12. Authors concluded that the 
situation calls for optimization 
of all the relevant patient factors 
including anticoagulant therapy, 
use of appropriate technique, 
and the appropriate imaging 
modalities. However, spinal 
stenosis has been described as a 
significant risk factor to develop 
epidural hematoma with epidural 
injections. 
Table 7 (cont.). Reports of  bleeding and epidural hematoma in patients after discontinuation of  antithrombotic therapy after 
interventional techniques.
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Table 7 (cont.). Reports of  bleeding and epidural hematoma in patients after discontinuation of  antithrombotic therapy after 
interventional techniques.








Clopidogrel 10 days This is a case report in a 49-year-old male for placement of 
spinal cord stimulation trial leads for chest pain.    Leads were 
attempted to be placed at L1-L2 with Tuohy needle under live 
fluoroscopic guidance contacting the L2 lamina with loss of 
resistance technique to the air. Subarachnoid puncture was 
noted with clear fluid flowing freely from the Tuohy needle. 
The needle was withdrawn into the epidural space and a 
spinal lead advanced to mid C7.    Post operatively patient 
reported a positional headache accompanied by nausea 
and vomiting. This progressively worsened over the course 
of the day, changing in character with loss of positional 
component accompanied by emesis. His CT scan of the 
head showed a large subdural hematoma. Neurosurgical 
consultation was carried out and the patient underwent 
emergency craniotomy.    The remaining post-surgical 
course was uneventful; however, on the postoperative day 3 
patient recalled falling at home one day prior to the spinal 
cord stimulator implant, striking his head without loss of 
consciousness. 
Even though this case presents 
acute intracranial subdural 
hematoma secondary to 
unintentional dural puncture 
during placement of permanent 
spinal cord stimulator lead, it 
also raises questions in reference 
to the causal relationship of the 
procedure and development 
as there was history of a fall.    
Even then, there is need for 
careful follow-up of patients 
with a known post dural tear. 
Failure to identify uncommon 
adverse events in patients 
with complicated spinal cord 
stimulator implantation may lead 
to permanent injury. 
Xu et al (188) Warfarin, Aspirin, 
Enoxaparin
6 days and 24 
hours before 
procedure
Warfarin and aspirin stopped 6 days before the procedure 
with bridging over to enoxaparin twice daily, with the last 
enoxaparin dose at least 24 hours before the procedure. 
A 78-year old woman underwent lumbar interlaminar 
epidural injection under fluoroscopic guidance.    30 hours 
after the 3rd lumbar interlaminar epidural injection, the 
following morning after the 2nd shot of enoxaparin, the 
patient developed excruciating radicular leg pain.     CT 
scan of the lumbar spine was inconclusive. Subsequently, 
MR imaging of the lumbar spine showed a lumbar epidural 
hematoma that spanned from L2 to L5 causing severe thecal 
sac compression.    She was treated with bilateral lumbar 
laminectomies, foraminotomies and hematoma evacuation 
from L2-L5. The patient had unremarkable postoperative 
course. The epidural hematoma developed despite 
cessation of all drugs within the guidelines and restarting of 
enoxaparin within the guidelines.
Despite strict adherence to 
anticoagulation guidelines, 
epidural hematoma developed. 






6 days and 
Enoxaparin 
was stopped 
for over 24 
hours prior to 
the injection. 
INR was 1.2
A patient with renal insufficiency received an epidural 
injection at L3-L4 interspace.    Enoxaparin regimen was 
reinstituted 24 hours after the procedure. 48 hours after 
the procedure she reported 100 times worse back pain 
in the same location as before the epidural injection.    
Magnetic resonance imaging study showed severe central 
canal stenosis centered at L3-4 from a posterior epidural 
hematoma. Epidural hematoma extended from L2 through 
L4.    Her anticoagulation regimen was discontinued 
and managed conservatively. The second day the patient 
experienced increased numbness and weakness in the 
lower extremities. Subsequent MRI revealed increasing 
size of the epidural hematoma extending from L1 to L5.     
Decompression laminectomies were performed from L2 to 
L4 and dexamethasone was given for 3 days. 
Patient developed epidural 
hematoma after epidural injection 
despite strict adherence to the 
guidelines for neuraxial anesthesia 
and anticoagulation regarding 




Aspirin (325 mg) 7 days A 62-year-old woman underwent an uncomplicated cervical 
epidural steroid injection. She developed acute onset of axial 
pain followed by progressive quadriparesis within a matter 
of 8 hours.     Emergency CT scan suggested posterior cord 
displacement consistent with an anterior spinal hematoma 
from C3 through C5.    She was taken to the operating room 
and appropriate decompression was carried out showing 
anterior subdural hematoma. Patient continued to be 
quadriplegic, even though rapidly gained full function in 
the left upper and lower extremities. She developed acute 
meningitis and cardiac arrests and finally died.
Epidural hematoma can occur 
even after appropriate cessation 
of aspirin. Despite rapid diagnosis 
and surgical intervention, the 
outcome was bad in this case.
NSAIDs = non-steroidal anti-inflammatory drugs; MRI = magnetic resonance imaging; INR – international normalized ratio; CT – computed 
tomography
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Antithrombotics and Anticoagulants Guidelines
Table 9 shows summary reports of a number of 
epidural hematomas with epidural injections, acupunc-
ture and dry needling, and spinal cord stimulation lead 
placement in patients without antithrombotic therapy, 
with antithrombotic therapy withheld for appropriate 
duration, and with antithrombotic therapy continued 
(Figs. 2-4). A total of 38 epidural hematomas were 
described in 35 case reports. There were 20 in cervical 
spine, 8 in thoracic spine, and 10 in lumbar spine. Of 
these, 19 patients were on no antiplatelet therapy, 11 
patients had their antithrombotic therapy discontin-
ued, and 8 continued antithrombotic therapy. Further, 
as shown in Fig. 4, epidural injections were responsible 
for 25 cases of hematomas, 7 cases were secondary to 
acupuncture or dry needling and 6 were related to spi-
nal cord stimulation. There was one case report of cau-
dal epidural injection with cilostazol (202), and in one 
case report we were unable to obtain full manuscript 
(207). Cases of chronic subdural hematoma and cases of 
abdominal hematomas were not included. 
Table 9. Reports of  epidural hematomas.









Warfarin – 1 
Aspirin – 1
Fish oil – 2
Indomethacin – 1
Clopidogrel – 1 

















Aspirin + Clopidogrel – 1, 
Warfarin – 3
Dabigatran – 1
Cilostazol (caudal) -- 1
TOTAL 4 5 1 10
COMBINED TOTALS 19 11 8 38
Fig. 2. Epidural hematoma incidence based presence or 
absence of  anticoagulant/antiplatelet therapy.
Fig. 3. Epidural hematoma incidence based on spinal 
regions.
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4.0 GuIdelInes And recoMMendAtIons
Guidelines and recommendations were based on risk 
stratification, pharmacology of antithrombotics and anti-
coagulants, and application of available evidence.
4.1 Risk Stratification 
Interventional techniques performed in the spine 
and other regions for chronic cancer and noncancer pain 
patients face variable risks depending on anticoagulant or 
antithrombotic therapy, age, anatomy, the specific region 
of interest, and obesity. Consequently, various authors 
have described procedural classification according to the 
potential risk for serious bleeding. 
Raj et al (212) stratified risk score based on technique 
related bleeding risk and patient-related bleeding risk 
factors. This risk classification took various factors into 
consideration including a sharp or blunt needle, use of 
fluoroscopy and lack of fluoroscopy. 
Breivik et al (36) in a comprehensive topical review 
of reducing risk of spinal hematoma from spinal epidural 
and pain procedures based their recommendations on 
extensive review of 166 case reports published since 1994 
through 2015 (52,53), pharmacology of drugs, and avail-
able clinical evidence relating to complications whether or 
not the antithrombotics were continued or discontinued.
Narouze et al (40) provided guidance for intervention-
al spine and pain procedures in patients on antiplatelet 
and anticoagulant medications. They provided extensive 
review of the literature, considered pharmacology, and 
current literature with development of risk stratification.
Deer et al (39) provided recommendations on bleed-
ing and coagulation management in neurostimulation 
devices. They also provided bleeding risk stratifications 
for neuromodulation procedures. Their classification 
showed spinal cord stimulation trial and implant, 
dorsal root ganglion stimulation, and intrathecal 
catheter and pump implant as high to intermediate 
risk neuromodulation procedures. Further, they clas-
sified deep brain stimulation and motor cord stimu-
lation as high-risk neuromodulation procedures. This 
is in contrast to other guidance where spinal cord 
stimulation trial and implant, dorsal root ganglion 
stimulation, and intrathecal catheter and pump im-
plant are considered as high risk.
Oprea et al (20) published risk stratification, 
perioperative, and periprocedural management of 
patients receiving anticoagulant therapy based on 
bleeding risk for each procedure, pharmacology, and 
evidence of risk of development of bleeding compli-
cations as well as thromboembolic risks.
Lagerkranser (52) and Lagerkranser and 
Lindquist (53) published extensive review of neur-
axial blocks and spinal hematoma with review of 
100 case reports published from 1994 to 2015 with 
demographics and risk factors, as well as diagnosis, 
treatment, and outcome. They concluded that the 
annual number of published cases of spinal hema-
toma after central neuraxial blocks increased during 
1994 to 2015 compared to previous years. Case re-
ports on elderly women accounted for this increase; 
however, they also emphasized that anti-hemostatic 
drugs, heparins in particular, still continue to be ma-
jor risk factors for developing post central neuraxial 
blockade spinal bleedings. They also described other 
risk factors related to hemostasis and spinal disorders 
and complicated blocks, especially spinal stenosis and 
“bloody taps,” whereas multiple attempts do not 
seem to increase the risk of bleeding (Table 10). Fur-
ther, they conceded that in a large number of cases, 
no risk factor was reported. 
Lagerkranser (52) also identified patient-related 
risk factors as shown in Table 10. Topping the list of 
the risk factors is spinal disease in general and spinal 
stenosis in particular. Surprisingly, INR of ≥ 1.5 was the 
least related risk factor second only to liver disease. 
Among the drug-related risk factors, these were 
the most common risk factors with the intake of anti-
hemostatic drugs in 105 of 166 cases (63%), and with 
no drug therapy in 37% of cases. Further, in 47 of 
the cases, more than one anti-hemostatic drug was 
implicated in 12 cases in 3 such drugs. Table 11 shows 
drug related risk factors with low molecular heparin 
topping with 31% of the cases, aspirin at third level 
Fig. 4. Epidural hematoma cases reported based on type of  
procedure.
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with 16% of cases, vitamin K antagonist with 11% of 
the cases, NSAIDs also at 11%, and adenosine diphos-
phate (ADP)-receptor inhibitors and phosphodiesterase 
inhibitors at 2.5% and 1.3% respectively. 
They also concluded that guidelines issued around 
the turn of the century do not seem to have affected 
the number of published reports. They also concluded 
that the complications continue to occur despite fol-
lowing the appropriate guidelines and strict adherence 
to the recommendations. Consequently, they concluded 
that there are no guarantees against such bleedings to 
occur, even if guidelines are strictly followed.
Lagerkranser (52) and Lagerkranser and Lindquist 
(53) also concluded that suspicion of a spinal hematoma 
calls for the consultation of an orthopedic or neurologi-
cal surgeon without delay. Surgical evacuation within 
12 hours from the first sign of motor dysfunction seems 
to lead to the best outcome, even though many pa-
tients operated on later than 24 hours did regain full 
motor function. They also concluded that despite the 
poor prognosis after surgical evacuation of spinal he-
matoma, the outcomes after central neural blockade in 
general have improved significantly over time.
Our data analysis in this report showed interlami-
nar epidural injections, spinal cord trial lead placement 
through interlaminar approach, and spinal stenosis as 
risk factors. Overall, as shown in Fig. 2, when antithrom-
botics were continued, epidural hematomas occurred in 
8 patients compared to 19 with no antithrombotic ther-
apy and 11 with antithrombotic therapy appropriately 
discontinued. This provides a ratio of 27% incidence 
of hematomas when antithrombotics were continued 
compared to 73% with either no antithrombotics, or 
with appropriate discontinuation of antithrombotics. 
There were larger number of patients in the group 
where antithrombotics were discontinued with 11 com-
pared to 8 in continued group. The majority of the he-
matomas were reported in the cervical region with 20, 
followed by 10 in the lumbar region and 8 in thoracic 
region (Fig. 3). Further analysis also showed that 25 of 
38 cases were related to epidural injections, 7 were re-
lated to either acupuncture or dry needling, and 6 were 
related to spinal cord stimulation (Fig. 4). Thus, epidural 
injection, specifically in the cervical spine, is considered 
as high risk, along with spinal cord lead placement. This 
is illustrated in Figs. 5 to 7. As shown in Fig. 5, cervical 
epidural hematoma incidence was highest in patients 
without any antithrombotic therapy with 11 patients, 
followed by continuation of antithrombotic therapy in 
5 patients, followed by in 4 patients where antithrom-
Table 10. Patient related risk factors as described in review of  
166 cases of  spinal hematoma.








Spina bifida occulta 1
Dural AV-fistula 1
Spinal AVM 1
Spinal disease (total) 37
Thrombocytopeniaa 13b 
Renal insufficiency 10
INR ≥ 1.5 6c 
Liver disease 4
a Platelet count < 150 × 10 9 /L. 
b Including 2 obstetric cases, one with HELLP (haemolysis, elevated 
liver enzymes, and low platelets), and one with eclampsia, and one 
patient with idiopathic thrombocytopenic purpura, discovered 
postlaminectomy. 
c In one case without anti-vitamin K treatment. 
Source: Lagerkranser M. Neuraxial blocks and spinal haematoma: 
Review of 166 case reports published 1994-2015. Part 1: Demograph-
ics and risk-factors. Scand J Pain 2017; 15:118-129 (52).
Table 11. Drug classes reported, in order of  frequency in 160 
cases of  spinal hematoma.
No. of cases 
(percentage) 
Low molecular weight heparin 50 (31)
Unfractionated heparin 39 (24)
Acetylsalicylic acid 25 (16)
Vitamin-K antagonists 17 (11)
Non-steroidal anti-inflammatory drugs 17 (11)
Dextran 6 (3.8)
Fibrinolytics 4 (2.5)
ADP receptor inhibitors 4 (2.5)
Phosphodiesterase inhibitor (dipyridamole) 2 (1.3)
Direct fXa inhibitor (rivaroxaban) 2 (1.3)
Direct thrombin inhibitor (dabigatran) 1 (0.6)
Fondaparinux 1 (0.6)
Selective serotonin receptor inhibitor 1 (0.6)
Source: Lagerkranser M. Neuraxial blocks and spinal haematoma: 
Review of 166 case reports published 1994-2015. Part 1: Demographics 
and risk-factors. Scand J Pain 2017; 15:118-129 (52).
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botic therapy was discontinued. Overall, in the 
cervical spine, in 67% of the patients develop-
ing hematoma formation, there were either 
no antithrombotics or antithrombotics were 
discontinued appropriately. Results were even 
more striking in lumbar spine as shown in Fig. 
7. Overall, there were 10 instances of lumbar 
epidural hematoma, 4 in patients without 
antithrombotic therapy, 5 with appropriate 
discontinuation and only one patient where 
it was continued with cilostazol which is 
rarely utilized and none of the guidelines 
recommend it to be discontinued. Thus, in 
the lumbar spine, only one patient or 10% of 
epidural hematomas were related to continu-
ation of antithrombotic therapy. In contrast, 
in the thoracic spine the results were similar 
to the cervical spine with 6 patients develop-
ing hematoma, either without anticoagulant 
therapy or after appropriate discontinuation 
(4+2) and in 2 patients with continuation of 
antithrombotic therapy with a 25% incidence 
of epidural hematoma in the thoracic spine in 
patients continuing antithrombotic therapy 
similar to cervical spine and higher than lum-
bar spine. 
The previous studies have shown low mo-
lecular weight heparin as the most frequently 
used drug followed by unfractionated hepa-
rin, followed by aspirin (Table 12). The pres-
ent assessment showed aspirin as the most 
common drug with a total of 7 of 38 patients; 
however, it was continued only in 3 patients; 
whereas it was discontinued in 4 patients. 
Warfarin was also common with or without 
enoxaparin; however, it was discontinued 
according to the guidelines. Clopidogrel was 
reported in 3 cases with discontinuation in 
2 patients and continuation in one patient. 
Many of the commonly utilized antithrom-
botics have not been identified in the present 
analysis.
Multiple factors and the available lit-
erature in reference to the adverse conse-
quences of anticoagulant and antithrombotic 
therapy with interventional techniques were 
utilized in developing risk stratification. The 
following classification for interventional 
techniques has been developed (Table 13) 
(1,20,31-40,52,53,198-200,212). The classifica-
tion describes low risk, intermediate risk, and 
Fig. 5. Cervical epidural hematoma incidence bbased presence or 
absence of  anticoagulant/antiplatelet therapy.
Fig. 6. Thoracic epidural hematoma incidence based presence or absence 
of  anticoagulant/antiplatelet therapy.
Fig. 7. Lumbar epidural hematoma incidence based presence or absence 
of  anticoagulant/antiplatelet therapy.
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high-risk procedures. However, based on comorbid 
medical conditions and other risk factors of coagulopa-
thies and concurrent use of other anticoagulants and 
antiplatelets, the procedural risk classification may be 
changed from low risk to intermediate, intermediate to 
high risk.
Of all the low risk procedures as shown in Table 13, 
caudal epidural injection was the only one which has 
reported an epidural hematoma with continuation of 
cilostazol (202). This is extremely unusual and probably 
coincidental. Consequently, with caudal epidural injec-
tions and other low risk procedures, antithrombotic 
and anticoagulant therapy may be continued with the 
appropriate guidelines.
Intermediate risk procedures include multiple 
procedures performed, constituting a great propor-
tion of procedural prevalence. This risk stratification is 
somewhat different from the one proposed by ASRA 
(40). Justifiably we have included caudal percutane-
ous adhesiolysis into intermediate risk procedures as 
there have not been any case reports. Further, lum-
bar transforaminal epidural injections at L4, L5, S1, 
and sympathetic blocks have been included in these 
categories due to one or 2 case reports. Lumbar in-
terlaminar epidural injections performed between L5 
and S1 are included in intermediate risk procedures; 
whereas, procedures performed at L4-5 and at higher 
levels are included in high risk procedures. A majority 
of the lumbar epidural hematomas developed despite 
discontinuation of antithrombotic therapy and these 
were performed above L5-S1 interspace. If epidural 
hematoma develops at L5-S1 it will have significantly 
higher space availability to be asymptomatic and to be 
managed conservatively. 
The high risk procedures include the majority of 
the procedures performed in the cervical and tho-
racic spine. These guidelines are in contrast to ASRA 
guidelines with the inclusion of cervical, thoracic, 
and high lumbar above L5-S1 due to the available 
literature and potential issues related to epidural 
hematoma requiring surgical exploration and spinal 
cord damage.
Table 12. Drug classes reported in order of  frequency.
Continued Discontinued Total
None 19
Aspirin discontinued 4 3 7
Warfarin discontinued 0 4 4
Clopidogrel 1 2 3
Fish oil 2 0 2
Indomethacin 1 0 1
Cilostazol 1 0 1
Dabigatran 0 1 1
Table 13. Classification of  interventional techniques based on the potential risk for bleeding.
Low-Risk Procedures Intermediate-Risk Procedures* High-Risk Procedures*
1. Trigger point and muscular 
injections (including 
piriformis injection)
2. Peripheral joints 
3. Peripheral nerve blocks
4. Sacroiliac joint and ligament 
injections and nerve blocks
5. Caudal epidural injections
6. Ganglion impar blocks
1. Facet joint interventions (intraarticular injections, 
nerve blocks and radiofrequency neurotomy)
2. Lumbar transforaminal epidural injections at L4, 
L5, S1
3. Lumbar intradiscal procedures
4. Hypogastric plexus blocks
5. Lumbar sympathetic blocks
6. Peripheral nerve stimulation trial and implant
7. Pocket revision and implantable pulse regenerator/
intrathecal pump replacement
8. Caudal percutaneous adhesiolysis
9. Lumbar percutaneous disc decompression (L4/5 
or below)
10. Lumbar vertebral augmentation (below L4)
11. Intervertebral spinous prosthesis
12. Lumbar discography 
13. Lumbar interlaminar epidural injections at L5-S1
1. Cervical, thoracic, and high lumbar (above L4-L5) 
interlaminar epidurals
2. Cervical, thoracic and lumbar above L3 
transforaminal epidural injections
3. Spinal cord stimulator trial and implant 
4. Percutaneous adhesiolysis with interlaminar or 
transforaminal approach
5. Percutaneous disc decompression (above L4/5)
6. Sympathetic blocks (stellate ganglion; thoracic 
splanchnic, celiac plexus)
7. Thoracic and cervical intradiscal procedures
8. Vertebral augmentation, lumbar (above L4), 
thoracic and cervical 
9. Intrathecal catheter and pump implant
10. Interspinous prosthesis and MILD®
*Patients with high risk of bleeding (e.g., old age, history of bleeding tendency, concurrent uses of other anticoagulants/antiplatelets, liver cirrhosis 
or advanced liver disease, and advanced renal disease) undergoing low or intermediate-risk procedures should be treated as intermediate or high 
risk, respectively.
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4.2 Pharmacologic Aspects and Hemostasis 
Monitoring
 The main categories of antithrombotics and anti-
coagulants are described as; platelet inhibitors, interfer-
ing with platelet aggregation (clumping) and thrombus 
formation; anticoagulants interfering with formation 
of the clotting, thereby reducing fibrin formation and 
preventing clots from forming and expanding; and fi-
brinolytics interfering with the final clot.
Monitoring of hemostasis is performed with mul-
tiple standard tests including platelet count, activated 
partial thromboplastin time (APTTa), and INR. The nor-
mal platelet count is x 109 L-1 from 150 to 350 with 
recommended counts of greater than 50 for vital life-
threatening indication, greater than 80 for strong indi-
cation, and greater than 100 for weak indication (36). 
A normal INR is considered as 0.9 to 1.2. Consequently, 
for epidural injections, INR of less than 1.5 is ideal for 
high risk and moderate risk procedures, and less than 
1.8-2.00 is ideal for low risk procedures. 
Additional advanced hemostatic tests for monitor-
ing of hemostasis include multiple viscoelastic tests like 
thromboelastography or thromboelastrometry exten-
sively used to evaluate liver disease (213). However, this 
parameter has been studied for safe epidural catheter 
removal with the conclusion that the tests were not 
well validated in this context and there were frequent 
false negative test results (214,215). Even then, a clearly 
abnormal curve indicates deranged hemostasis and 
must be taken seriously (215,216).
4.2.1 NSAIDS and Aspirin 
NSAIDs inhibit cyclooxygenase enzymes COX1 and 
COX2, which inhibit prostaglandin production to de-
crease the inflammatory response. Thus, NSAIDs have 
analgesic effects and are used for minimizing pain. 
Thromboxane A2 is produced via COX1 enzyme activ-
ity, which is a potent thrombus activator. Aspirin is an 
irreversible inhibitor of COX1 and has significant clini-
cal benefits for preventing thrombus formation. In re-
sponse to aspirin, more prostacyclin is produced by en-
dothelial cells, but there is no additional thromboxane 
made as there are no nuclei in platelets, thus, there is 
a greater percent of prostacyclin to thromboxane, thin-
ning the blood. Elevated bleeding risk is a concern for 
a small portion of patients, but adverse effects are rare. 
Prostacyclin (PGI2) synthesis from vascular endothelial 
cells is dependent on COX2 and has anti-platelet effects. 
High doses of aspirin reduce PGI2 production which 
can abolish the anti-platelet effect of low dose aspirin. 
Low-dose aspirin anti-platelet effects last for 7-10 days, 
as bone marrow directed platelet renewal is required 
for clotting to resume. Low-dose aspirin therapy is well 
established to reduce the risk of cardiovascular events 
in patients with acute coronary syndromes, cerebral 
infarct, or occlusive vascular disease (217). However, 
recently published large scale evidence (15-19) shows 
lack of benefit with aspirin for primary prevention of 
cardiovascular events, while it does increasethe risk of 
bleeding. 
The data reported by Lagerkranser et al (52) and 
the data derived from the present analysis are shown in 
Tables 11 and 12. Aspirin was the most common drug of 
the 19 cases of epidural hematoma reported in this se-
ries with 7 with use of aspirin. Four patients discontin-
ued aspirin appropriately and 3 patients continued. In 
the data by Lagerkranser et al (52), aspirin was utilized 
in 16% of patients reporting spinal hematoma of 160 
cases constituting a total of 18% in the present series. 
Eight percent continued aspirin and 11% discontinued 
aspirin. The most common drug reported in Lagerkran-
ser et al (52) series was low molecular weight heparin 
in 31% of the cases and Warfarin in 11% of the cases. 
In the present series, Warfarin with or without low mo-
lecular weight heparin was utilized in 4 patients with 
11% utilization. 
Table 14 shows pharmacokinetic and pharmaco-
dynamic characteristics of aspirin and NSAIDs. Time to 
50% recovery of platelet function with aspirin is shown 
as 3 days (36). Antiplatelet function of irreversible in-
hibitors is dependent mainly on platelet regeneration 
than drug half-life. While bleeding complications have 
been reported without any drug therapy, majority of 
the bleeding complications were related to aspirin in 
18% while 11% discontinued and 7% continued. 
For other NSAIDs, unlike aspirin, the platelet effects 
of these drugs are directly related to systemic plasma 
drug concentrations and influenced by the pharmaco-
kinetic clearance of these medications. It takes approxi-
mately 5 half-lives for systematic elimination. Recent 
recommendations (40) have revised recommendations 
for aspirin, whether to continue or discontinue in the 
perioperative period for interventional pain proce-
dures. Decision-making is based on the reason for 
aspirin utilization, a multitude of risk factors including 
vascular anatomy surrounding the target area, degree 
of the invasiveness of the procedure, and potential 
sequelae associated with perioperative bleeding. Thus, 
aspirin for primary prophylaxis can be stopped without 
any hesitation. The major consideration in withholding 
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aspirin is the thromboembolic risk. Based on the avail-
able evidence, it appears that aspirin discontinuation 
for 4 days may be sufficient. In contrast, for non-steroid 
anti-inflammatory agents, recommended discontinu-
ation by ASRA is one day for diclofenac, ibuprofen, 
and Ketoralac. Recommended discontinuation time is 
2 days for etodolac and indomethacin. Discontinuation 
is about 4 days for meloxicam and Naprosyn, 6 days for 
nabumetone, and 10 days for piroxicam and oxapro-
zin. However, the evidence for stopping non-steroidal 
anti-inflammatory agents other than aspirin seems to 
be very limited. Stopping these drugs may become a 
practical issue and patients may not like it to stop all 
the drugs and complain of significantly more pain. Con-
sequently, based on available, very limited, evidence, 
the clinician may continue or discontinue.
4.2.2 ADP Receptor Inhibitors
ADP-receptor inhibitors inhibit platelet aggrega-
tion. The drugs in this category utilized for clinical 
applications include Clopidogrel (Plavix®), Prasugrel 
(Effient®), Ticlopidine (Ticlid®), and Ticagrelor (Bril-
inta®). Table 15 shows comparative pharmacokinetics 
and pharmacodynamics of ADP-receptor inhibitors.
Clopidogrel is the prototypical thienopyridine drug 
that inhibits the P2Y12 receptor. The P2Y12 receptor is 
activated by ADP binding and promotes platelet aggre-
gation. Depending on the dosage schedule, the maximal 
platelet aggregation inhibitory effects of clopidogrel 
are reached within 3 to 7 days. After discontinuation, 
recovery of platelet inhibition occurs 50% after 3 days 
and full recovery after one week (218) Eighty percent of 
subjects demonstrated normal platelet aggregation by 
the 4th day (218). Other studies have demonstrated the 
recovery of platelet function after cessation of aspirin in 
volunteers in surgical patients after 3 days in volunteers 
and within 4-6 days in surgical patients (211). In this 
study, by day 6, all of the subjects had restored platelet 
aggregation to at least 85% of the baseline level. 
Ticlopidine also belongs to the thienopyridine 
group and is maximally aggregated after 8 to 11 days 
of a 500 mg per day dosage schedule. After withdrawal 
of 72 hours, there is still a lingering effect as there is an 
irreversible inhibition of platelet function (219). Prasu-
grel acts by antagonizing ADP at the platelet’s purine 
receptors, and aggregation is thus noncompetitively 
and irreversibly inhibited. 
Prasugrel, or Effient, has significantly higher irre-
versible antiplatelet activity compared to clopidogrel 
with time to peak effect of one hour. Thus, administra-
tion of first dose results in around half of the platelets 
being inhibited within the first hour of taking this 
medication. Following three to five days of therapy, the 
steady-state inhibition of platelet aggregation reaches 
around 70% (220). As a prodrug, prasugrel is rapidly 
metabolized to active and inactive metabolites. These 
metabolites have varying elimination rates, although 
the active metabolites have an elimination half-life of 7 
hours, with a wide range of 2-15 hours (221).
Lastly, a distinct ADP-receptor inhibitor is Ticagrelor, 
which directly inhibits P2Y12 receptors (222-224). While 
Ticagrelor is metabolized to active metabolites, the 
original compound is responsible for the majority of the 
inhibitory effects (223,224). A notable advantage of Ti-
cagrelor is rapid effect, with peak platelet inhibition after 
2 to 4 hours of intake (225). These medications undergo 
hepatic conversion to active metabolites, which are then 
eliminated by the kidneys (226). In addition, glycoprotein 
Table 14. Characteristics of  aspirin and NSAIDs.
Aspirin or acetylsalicylic acid (Oral 
Low Dose)
NSAIDs
Target COX -1 irreversible COX-1 reversible, COX-2
Time to peak effect 0.5 hours Varies
Plasma Half Life 0.5 hours Variable from 1 to 72 hours
Renal elimination + +
Time to 50% recovery of platelet function 3 days 1 day
Hours to C-Max 0.5 hours ~0.5 hours
Metabolism Hepatic Hepatic
Bioavailability 60% 50-95%
Antihemostatic effect ++ +
NSAID = non-steroidal anti-inflammatory drug; COX = cyclo-oxygenase
Rating of antihemostatic effect and renal elimination: (+) = insignificant; + = low; ++ = moderate; +++ = pronounced; ++++ = high.
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IIB/IIIA receptors are less activated, causing a reduction in 
fibrinogen fixation and platelet crosslinking.
ADP inhibitors were described as responsible for 
the formation of epidural hematoma after central 
neuraxial blockade in 2.5% of 160 cases or 4 cases. In 
the present assessment, clopidogrel either in combina-
tion with aspirin or ticlopidine was utilized in a total of 
3 cases, with 2 cases being discontinued appropriately 
and one case it was continued. Thus, ADP inhibitors 
with reports available for only one or 2 drugs showed 
any relevance in 8% of the cases with only one case or 
2.6% of cases where it was continued and in 5% of the 
cases it was discontinued. This is similar to the reports 
from Lagerkranser et al (52).
4.2.3 Phosphodiesterase (PDE) Inhibitors
Phosphodiesterase inhibitors include Cilostazol 
(Pletal®) and Dipyridamole (Persantine®). These medi-
cations selectively inhibit phosphodiesterase, which 
leads to an increase in intracellular cyclic adenosine 
monophosphate (cAMP) and subsequent reversible 
inhibition of platelet aggregation (227). Additionally, 
Dipyridamole blocks thromboxane synthase, the throm-
boxane receptor, and the cellular reuptake of adenos-
ine into platelets, red blood cells, and endothelial cells. 
This results in increased adenosine in the extracellular 
space and inhibition of formation of cytokines and 
proliferation of smooth muscle cells. Absorption of Di-
pyridamole occurs in the gastrointestinal tract and is pH 
dependent. Gastric acid suppressors and proton pump 
inhibitors inhibit absorption, which can be prevented 
via buffered additives added to the medication (228). 
An additional advantage of Cilostazol is inhibition of 
PDE3A, which is selective to vascular smooth muscle 
cells and results in vasodilatation. Cilostazol is admin-
istered at 100 mg twice daily and reaches maximum 
plasma levels after three hours. It is eliminated via 
hepatic metabolism and is excreted in the urine (229). 
Thus, cilostazol is contraindicated in those with severe 
renal insufficiency. For interventional procedures, 
phosphodiesterase inhibitors have been considered as 
safe to continue. However, risk may increase with ad-
dition of aspirin. Limited data exists evaluating the risk 
of perioperative surgical bleeding with cilostazol (40) 
and no standard perioperative guidelines are available 
(230). Further, if the medication is discontinued, at 50 
hours (approximately 5 half-lives), less than 5% of the 
drug remains in plasma and improvements in platelet 
aggregation have been demonstrated, despite continu-
ous prior dosing (210,231).
There is a single case report of bleeding complica-
tions associated with interventional technique (202). 
In this case report, the patient underwent a caudal 
epidural injection developing epidural hematoma 
Table 15. Comparative pharmacokinetics/pharmacodynamics of  ADP-receptor inhibitors.
 Clopidogrel (Plavix®) Prasugrel (Effient®) Ticlopidine (Ticlid®) Ticagrelor (Brilinta®)
Target P2Y12ADP P2Y12ADP
P2Y12ADP, also inhibits 




activity ++ +++ ++ ++++
Time to Cmax 3-7 days 3-5 days 8-11 days 2-4 hours
Time to peak effect 4 hours to 4 days 1 hour 3-5 days 2.5 hours
CYP metabolism
CYP1A2, CYP2B6, 
CYP2C9, CYP2C19 and 
CYP3A4/5
CYP450-mediated 
(primarily CYP3A4 and 
CYP2B6) 
Cytochromes P450 CYP3A4
Bioavailability > 50% ≥ 79% > 80% 36%
Protein binding 94–98% Active metabolite: ~98% 98% >99.7%
Plasma half-life 7-8 hours (inactive metabolite)
~7 hours (range 2 hours to 
15 hours)
12 hours (single dose) 4-5 
days (repeated dose)
7 hours (ticagrelor), 8.5 
hours (active metabolite 
AR-C124910XX)
Renal elimination 50% kidney, 46% biliary
Urine (~68% inactive 
metabolites); feces (27% 
inactive metabolites)
Renal and fecal Biliary
Time to 50% recovery 
of platelet function 3 days 3 days 6 days 1.5 days
CYP = cytochrome P450
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extending from L2 through S1 with concomitant cen-
tral canal compromise, severe at L2-3 and L3-4 levels. 
This patient received, in the past, lumbar interlaminar 
epidural injection without any side effects. Emergency 
decompression laminectomy was carried out with 
the patient making full recovery. This is the only case 
report in interventional techniques. Cilostazol alone 
without aspirin is recommended to be continued dur-
ing interventional techniques. Lagerkranser et al (52) 
also reported 2 cases of phosphatase inhibitors with 
dipyridamole with an incidence of 1.3% in 160 cases. 
Overall cilostazol is considered as a low risk drug and its 
continuation is appropriate.
4.2.4 Glycoprotein GPIIb/IIIa Inhibitors
A final common component of platelet aggrega-
tion is the glycoprotein IIb/IIIa receptor. Specialized 
medications inhibit this receptor, potently inhibiting 
platelet aggregation while being reversible (172). 
Abciximab (ReoPro®) is a Fab fragment of a hu-
manized monoclonal antibody directed against the 
GFPIIb receptor. Abciximab inhibits over 80% of ADP-
induced platelet aggregation and is given via IV admin-
istration. Additionally, thrombin generation is inhibited 
by Abciximab, which quickly binds to platelets with 
high affinity.
Eptifibatide (Integrilin®) is a cyclic peptide inhibi-
tor of the fibrinogen binding site on the GPIIb receptor. 
Tirofiban (Aggrastat®) is an additional glycoprotein IIb/
IIIa receptor inhibitor, reaching maximum efficacy after 
4 hours of administration, with 50-80% inhibition of 
platelet aggregation (232). Platelet function normalizes 
8 to 24 h after stopping the IV infusion.
There were no case reports secondary to devel-
opment of epidural hematoma in patients receiving 
glycoprotein IIB/IIIA. In addition, it appears that these 
drugs are not commonly used for prevention of throm-
boembolic activity. 
4.2.5 Low-Molecular Weight Heparin
Low molecular weight heparins (LMWHs) inhibit 
the coagulation cascade via binding to antithrombin, 
which leads to a conformational change of antithrom-
bin, which accelerates inhibition of factor Xa. LMWH 
has advantages: relatively high bioavailability, longer 
half-life, and ability for use once per day. Maximum 
efficacy levels are observed after 3-4 hours post subcu-
taneous administration, and elimination occurs after 
4-6 hours in those with normal renal function (233). 
High molecular weight heparins (HMWH) catalyze the 
inhibition of clotting factors IXa, Xa and thrombin by 
greatly enhancing antithrombin III activity, by causing 
a conformational change in ATIII exposing its reactive 
site. Testing is required to determine the dose effect 
on coagulation via partial thromboplastin time (PTT). 
HMWH is not absorbed by GI tract due to its large 
molecular weight, therefore IV or SC injection must 
be used. The short half-life of HMWH approximately 
1h) means frequent injections or continuous infusion, 
and it is thus not considered suitable in an outpatient 
setting.
Low molecular weight heparin is one of the com-
monly used drugs and has been implicated in multiple 
cases of epidural hematoma. Lagerkranser et al (52) 
showed low molecular weight heparin being respon-
sible for the highest number of cases in 31% of the 
reports. Our reports also show 2 cases of warfarin with 
bridging with LMWH being responsible for epidural 
hematoma (188,189), both in the lumbar spine. 
4.2.6 Warfarin
Oral anticoagulants inhibit the synthesis of vitamin 
K-dependent clotting factors, which are factor II, VII, 
IX, and X. Warfarin blocks the gamma-carboxylation 
of glutamate residues in prothrombin and factors VII, 
IX, and X. This results in biologically inactive coagula-
tion factor molecules. Vitamin K epoxide reductase is 
the enzyme that catalyzes the carboxylation reaction. 
Therapeutic doses of warfarin inhibit vitamin K epoxide 
reductase, which prevents the reductive metabolism of 
the inactive vitamin K epoxide to its active hydroqui-
none form. Synthesis is the primary target of oral an-
ticoagulants (warfarin), therefore the effects of these 
medications are not apparent until previously-existing 
clotting factor turnover has occurred. Factor half-lives 
vary, from factor VII at 6-8 hours to factor II at 50-80 
hours (234). Thus, it has a slow onset of action (8-12 
hours) as existing clotting factors must be depleted, 
and the maximal effect occurs 3-5 days after admin-
istration. Warfarin is monitored by PT and INR, which 
is a normalized ratio of the patient’s PT to that of a 
control sample (234). Age, female gender, and preex-
isting medical conditions such as hepatic, cardiac, and 
renal disease modify the patient’s response to warfarin. 
Asian patients, for example, have higher sensitivity to 
warfarin and require lower doses than those patients 
of European descent (234). Dietary changes may alter 
the patient’s clotting ability, and those on Warfarin are 
advised to avoid grapefruit and cranberry products, 
eat a consistent amount of leafy greens and other high 
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vitamin K containing foods and are advised to limit 
herbal supplement intake of garlic, ginger, gingko bi-
loba, ginseng, and fish oil. Warfarin may be reversed 
with administration of vitamin K, which is associated 
with multiple side effects. 
Warfarin is one of the most common drugs utilized 
in patients undergoing interventional techniques. Mul-
tiple complications have been reported with case re-
ports of epidural hematoma in patients with warfarin, 
despite if it was stopped as per the guidelines. 
Lagerkranser et al (52) reported warfarin contribut-
ing to spinal hematoma in 11% of the cases. Our report 
showed a total of cases of warfarin which were stopped 
appropriately with 2 of them also receiving enoxaparin 
with a similar incidence of around 10%.
4.2.7 Direct Thrombin Inhibitors
Direct thrombin inhibitors include Dabigatran 
(Pradaxa®), Argatroban (Acova™), Bivalirudin (An-
giomax®), Lepirudin (Refludan®), Desirudin (IPRIVASK®), 
and Hirudin as shown in Table 16. Of all the direct throm-
bin inhibitors, Dabigatran may be reversed by Idaruci-
zumab (Praxbind®), which was approved in 2015. 
Dabigatran etexilate is an oral anticoagulant and is 
a prodrug that is converted to dabigatran in the plasma. 
After an oral dose, the peak effect is reached within 2 to 
four hours, and plasma half-life is 13 hours on average 
(235). Dabigatran dose recommendations depend on 
renal efficacy in the patient receiving the medication. In 
those with a creatinine clearance of greater than 30mL/
minute, 150 mg is taken orally twice daily. For patients 
with lower creatinine clearance, 75mg twice daily is rec-
ommended. Dabigatran’s function is via factor inhibition 
and not clotting factor depletion, thus, the administra-
tion of clotting factors is anticipated to be less effec-
tive in reversing the effects of dabigatran. Dabigatran 

























Time to Cmax 2-4 hours 1-3 hours 2 minutes 4 hours 1-3 hours 3 hours
Time to peak 
effect 0.5 – 2 hours 2 hours 15 min 0.5-2 hours 2 hours 3-4 hours
Metabolism
Metabolized via 
conjugation into 4 
acyl glucuronides, 




thought to be 
metabolized by 
release of amino 
acids via catabolic 




from the C-terminus 






Bioavailability 3-7%(Oral) 100% IV 100%  IV application only
100% (injection 
or infusion) 100% 100% IV
Protein binding 35% 54% no n/a n/a n/a
Plasma half-life 13 hours 50 minutes




1.3 hours 2-3 hours 80 minutes
Renal elimination 80% urine Liver Yes Yes Yes Renal, about 48% (35% unchanged)
Linear PK Yes Yes Yes Yes Yes Yes




12 hours 2 hours 0.5 hours 1.5 hours 2 hours 2 hours
Reversal agents Praxbind NA NA NA NA NA
CYP = cytochrome P450; IV = intravenous
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is mostly cleared by the kidneys. In those with normal 
kidney function, Dabigatran is excreted in 1-2 days post-
discontinuation. This also depends on renal sufficiency 
of the patient taking the medication. There is one case 
report with epidural hematoma despite its discontinua-
tion for 7 days prior to interventional techniques (152). 
Lagerkranser et al (52) also reported on a case of spinal 
hematoma out of 160 cases. 
Argatroban is a small molecule direct thrombin 
inhibitor that is administered intravenously. It reaches 
steady-state plasma concentrations in 1-3 hours and is 
metabolized via the liver. It has a half-life of 50 minutes 
and is monitored by PTT. As it is metabolized hepati-
cally, it is a viable alternative for Dabigatran, which is 
metabolized renally (236).
Bivalirudin works by binding specifically to the 
catalytic site, in addition to the anion-binding exosite 
of circulating and clot-bound thrombin. Bivalirudin is 
cleared by the kidney and thus is dose-dependent on 
overall renal function. It has as a half-life of 25 minutes 
in those with normal renal function, but this may be 
doubled in those with severe renal insufficiency (237).
Desirudin is a subcutaneously administered direct 
thrombin inhibitor and is indicated for the prevention 
of venous thromboembolism after total joint replace-
ment. It is recommended that dosage adjustment and 
aPTT be monitored in patients with moderate-to-severe 
renal impairment. After intravenous administration, 
desirudin is removed rapidly via the renal system, with 
90% of the dose removed from the plasma within two 
hours. Plasma concentrations decline with a mean half-
life of 2-3 hours. Subcutaneous administration demon-
strates a half-life of 2 hours (238).
Hirudin has specific activity on fibrinogen and 
binds to and inhibits only activated thrombin, making 
it an extremely potent direct thrombin inhibitor. Thus, 
hirudin dissolves the formation of clots and thrombi 
and has therapeutic value in coagulation disorders. It 
is also able to act on complexed thrombin and does 
not alter other serum protein function or activity (239). 
Hirudin has a half-life of 2-3 hours and is monitored 
by aPTT, allowing close titration over a wide range of 
anticoagulative clinical desires. Activated clotting time 
(ACT) and prothrombin time (PT) are insensitive for 
monitoring hirudin .
4.2.8 Direct Factor Xa Inhibitors
Direct factor Xa inhibitors such as Rivaroxaban 
(Xarelto®) have been commonly used in the United 
States (Table 17). Of multiple Xa inhibitors available, 
apixaban (Eliquis) and rivaroxaban (Xarelto) can be 
reversed by Andexanet alfa (Andexxa®), a coagulation 
factor Xa (recombinant), which has been approved by 
the FDA for the urgent reversal of the anticoagulant 
effect in 2018 (240). 
Rivaroxaban (Xarelto) has dual renal and hepatic 
clearance, with around one-third of the drug being 
active with each route of metabolism. This dual route 
of clearance makes accumulation less likely than 
other medications that are solely hepatically or renally 











Target Xa Xa Xa Xa Xa
Time to Cmax 1-3 hours 2-4 hours 1-2 hours 3-4 hours 2 hours
Time to peak effect 3-4 hours 2-4 hours 1-2 hours 3-4 hours 2-3 hours
CYP Metabolism 15% 32% NR NR n/a
Bioavailability 66% 80% >45% 34% 100%
Transporter P-gp P-gp/BCRP P-gp P-gp P-gp
Protein binding 87% >90% 55% 60% 94%
Plasma Half-life 8-15 hours 9-13 hours 8-10 hours 37 hours 17-21 hours
Renal elimination 25% 33% 35% < 1% 100%
Linear PK Yes No Yes n/a Yes
Time to 50% recovery 
of Xa 12 hours 12 hours 12 hours 19-27 hours 12 hours
Reversal AGENTS Andexxa Andexxa NA NA NA
BCRP = breast cancer resistance protein; CYP = cytochrome P450; NR – not reported; P-gp = P-glycoprotein
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cleared. Rivaroxaban is orally administered and has a 
half-life of 5.7 to 9.2 hours. Plasma protein binding of 
rivaroxaban is 92-95%. One third of the absorbed dose 
is excreted in the urine, and two-thirds of the dose is ex-
creted as an inactive metabolite in the feces and urine. 
Rivaroxaban has the potential for drug interactions 
with medications that are P-glycoprotein inhibitors and 
those metabolized by CYP3A4 (241).
Apixaban (Eliquis®) is a specific factor Xa inhibitor 
like its counterpart, rivaroxaban. It is rapidly absorbed 
and reaches peak concentrations in 1-2 hours (242,243). 
Apixaban has an oral availability of 45% and has a rela-
tively complex elimination pathway with both direct 
renal and intestinal excretion, with the latter being the 
majority (243,244). Edoxaban (Savaysa® or Lixiana®) 
was approved for prevention of venous thromboembo-
lisms following lower limb orthopedic surgery in 2011 
and is an oral direct factor Xa inhibitor that inhibits free 
factor A and prothrombinase activity. It has also been 
approved for the prevention of stroke and systemic 
embolism. Peak plasma concentrations are reached 1.5 
hours after oral administration, and it has an elimina-
tion half-life of 10-14 hours when taken at 60mg once 
daily. It is excreted via both hepatic and renal systems 
(245). It is orally available, and not removed by dialysis.
Betrixaban (Bevyxxa®) is a potent oral factor Xa 
inhibitor that recently received FDA approval. It has 
exemplified promising results, as it has low hERG af-
finity and has reduced bleeding risk and prevented 
thromboembolism in clinical trials for orthopedic knee 
surgery (246-248). Betrixaban has the smallest per-
cent of renal clearance, is INR/PTT insensitive, and has 
minimal liver metabolism. Another selective factor Xa 
inhibitor, Fondaparinux (Arixtra®) is 100% bioavailable 
and achieves maximum concentration in 1.7 hours of 
administration (249). Its extended half-life of 17 to 21 
hours allows once-daily dosing (250).
There were no case reports in the present as-
sessment; however, Lagerkranser et al (52) showed 2 
cases of spinal hematoma with rivaroxaban yielding 
1.3% prevalence among 160 cases developing spinal 
hematoma.
4.2.9 Thrombolytic Agents
Fibrinolysis is caused by thrombolytic agents via 
conversion of plasminogen and thrombi to plasmin 
in order to destroy clots. These “clot busters” such as 
recombinant tissue-type plasminogen activator (tPA), 
streptokinase, urokinase, tenecteplase, and reteplase 
are enzymes that have effects on both circulating and 
tissue type plasminogen. The half-life of these throm-
bolytic drugs is generally a few hours, but the inhibition 
of plasminogen and fibrinogen may last for up to 27 
hours after administration (251).
There were no reports of epidural hematoma de-
velopment in patients receiving thrombolytic agents in 
our analysis; however, Lagerkranser et al (52) reported 
4 cases or 2.5% in the review of 160 cases of spinal 
hematoma. Among the miscellaneous agents, Chien et 
al (132) reported a case of epidural hematoma in a pa-
tient receiving fluoxetine, fish oil, and vitamin E. There 
was also another case report by Jenkie et al (137) with 
fish oil and the development of cervical epidural hema-
toma leading to surgical intervention for decompres-
sion. Lagerkranser et al (52) also reported one patient 
on selective serotonin receptor inhibitor of 160 cases.
4.2.10 Herbal/Alternative Therapies
Garlic has a dose-dependent effect on bleeding, as 
it contains a compound called ajoene. Derived from al-
licin, the compound that provides garlic’s flavor, ajoene 
inhibits granule release and fibrinogen binding and ad-
ditionally inhibits aggregation of platelets via a variety 
of mechanisms. Prostacyclin, forskolin, indomethacin, 
and dipyridamole are all altered via ajoene’s inhibition 
of granule release (252,253). Ginkgo Biloba has been 
used for thousands of years, and its mechanism is not 
entirely understood. Ginkgo is thought to antagonize 
platelet activating factor (PAF) and collagen leading to 
inhibition of platelet aggregation, resulting in several 
reports of spontaneous bleeding. Flavonol glycosides 
and terpene glycosides have been suggested to be 
the chemical compounds responsible for the increased 
bleeding events after intake of this medication (254). 
Ginseng is commonly used and reduces the effect of 
warfarin, declining peak INR levels. Ginsenosides are 
the major active ingredient of ginseng, and possibly 
induce cytochrome P450 enzymes to increase the me-
tabolism of Warfarin and thus reduce its effect.
5.0 recoMMendAtIons
Based on the evidence from review of the current 
literature with inclusion of available studies (1), case 
reports (38), multiple guidelines and reviews (1,20,31-
42,122-129) and consensus, the evidence appears as 
follows: 
1. There is good evidence for risk stratification by 
categorizing multiple interventional techniques 
into low-risk, moderate-risk, and high-risk. Also, 
www.painphysicianjournal.com  S109
Antithrombotics and Anticoagulants Guidelines
their risk should be upgraded based on other risk 
factors.
2. There is good evidence for the risk of thromboem-
bolic events in patients who interrupt antithrom-
botic therapy. 
3. There is good evidence supporting discontinuation 
of low dose aspirin for high risk and moderate risk 
procedures for at least 3 days, and there is moder-
ate evidence that these may be continued for low 
risk or some intermediate risk procedures.
4. There is good evidence that discontinuation of 
anticoagulant therapy with warfarin, heparin, 
dabigatran (Pradaxa®), argatroban (Acova®), 
bivalirudin (Angiomax®), lepirudin (Refludan®), 
desirudin (Iprivask®), hirudin, apixaban (Eliquis®), 
rivaroxaban (Xarelto®), edoxaban (Savaysa®, 
Lixiana®), Betrixaban(Bevyxxa®), fondaparinux 
(Arixtra®) prior to interventional techniques with 
individual consideration of pharmacokinetics and 
pharmacodynamics of the drugs and individual risk 
factors increases safety.
5. There is good evidence that diagnosis of epidural 
hematoma is based on severe pain at the site of 
the injection, rapid neurological deterioration, and 
MRI with surgical decompression with progressive 
neurological dysfunction to avoid neurological 
sequelae.
6. There is good evidence that if thromboembolic 
risk is high, low molecular weight heparin bridge 
therapy can be instituted during cessation of the 
anticoagulant, and the low molecular weight 
heparin can be discontinued 24 hours before the 
pain procedure.
7. There is fair evidence that the risk of thromboem-
bolic events is higher than that of epidural hema-
toma formation with the interruption of antiplate-
let therapy preceding interventional techniques, 
though both risks are significant.
8. There is fair evidence that multiple variables in-
cluding anatomic pathology with spinal stenosis 
and ankylosing spondylitis; high risk procedures 
and moderate risk procedures combined with 
anatomic risk factors; bleeding observed during 
the procedure, and multiple attempts during the 
procedures increase the risk for bleeding complica-
tions and epidural hematoma.
9. There is fair evidence that discontinuation of phos-
phodiesterase inhibitors is optional (dipyridamole 
[Persantine], cilostazol [Pletal]. However, there is 
also fair evidence to discontinue Aggrenox [dipyri-
damole plus aspirin]) 3 days prior to undergoing 
interventional techniques of moderate and high 
risk. 
10. There is fair evidence to make shared decision mak-
ing between the patient and the treating physi-
cians with the treating physician and to consider all 
the appropriate risks associated with continuation 
or discontinuation of antithrombotic or anticoagu-
lant therapy.
11. There is fair evidence that if thromboembolic risk 
is high antithrombotic therapy may be resumed 
12 hours after the interventional procedure is 
performed.
12. There is limited evidence that discontinuation of 
antiplatelet therapy (clopidogrel [Plavix®], ticlopi-
dine [Ticlid®], Ticagrelor [Brilinta®] and prasugrel 
[Effient®]) avoids complications of significant 
bleeding and epidural hematomas.
13. There is very limited evidence supporting the 
continuation or discontinuation of most NSAIDs, 
excluding aspirin, for 1 to 2 days and some 4 to 10 
days, since these are utilized for pain management 
without cardiac or cerebral protective effect.
Table 18 shows guidelines for antithrombotic 
medication management during interventional spine 
procedures. This table also shows comparisons of ASIPP 
proposed guidelines and ASRA published guidelines. 
These recommendations differ from our previously 
published guidelines, as well as from ASRA guidelines 
based on the present analysis of the evidence. 
General recommendations based on ASRA guide-
lines (40) are to discontinue the drugs for 5 half-lives; 
however, the exception to the 5 half-lives recom-
mendation should occur in individuals with hepatic 
dysfunction, and renal dysfunction including nephrotic 
syndrome.
6.0 dIscussIon And lIterAture revIew
6.1 Risk/Benefits of Antithrombotic Therapy
Cardiovascular disease in the United States con-
tributes to the most mortality with 610,000 deaths per 
year contributing to one in every 4 deaths (58). Throm-
botic complications contribute a significant proportion 
of cardiovascular related deaths. Various disorders 
contributing to thrombotic complications include ath-
erosclerotic cardiovascular disease, defined as acute 
coronary syndrome, ischemic heart disease, peripheral 
arterial disease, atrial fibrillation, and multiple other 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pain Physician: Guidelines Issue 2019; 22:S75-S128
S112  www.painphysicianjournal.com
ailments. These patients are widely prescribed with 
anticoagulants and antithrombotics in over 10% of the 
patients undergoing surgery or invasive procedures 
(255,256). However, a significant proportion of these 
patients may also undergo invasive procedures result-
ing in significant controversy. Significant risks have 
been described by withdrawing antiplatelet therapy, 
which included cardiovascular, cerebrovascular, and 
peripheral vascular thrombosis. In fact, a systematic 
review (69) showed a 3-fold increased risk for major 
adverse cardiac events and that the risk was magnified 
in patients with coronary stents. 
Estimates suggest that greater than two-thirds of 
sudden cardiac events (acute coronary syndrome or 
sudden cardiac death) and half of the postoperative 
myocardial infarctions follow initiation of an arterial 
plaque disruption and associated thrombosis (256-261). 
Parallel clinical data on cerebrovascular events are not 
known; however, acute coronary syndrome is associ-
ated with pro-inflammatory and pro-thrombotic states, 
which involve elevated levels of fibrinogen, C-reactive 
protein, and plasminogen activator inhibitor (262). In 
the postoperative period, endogenous catecholamines, 
increased platelet adhesiveness, and decreased fibrino-
lysis increase the risk of an acute coronary syndrome 
(256,260,263). 
There is evidence that discontinuation or interrup-
tion of antiplatelet therapy may result in hypercoagula-
bility with thrombosis or bleeding (69,264-273). Studies 
have determined that maintaining antiplatelet therapy 
throughout surgery is associated with an increase in 
blood loss of 2.5% to 20% with aspirin and 30% to 50% 
with a combined therapy of aspirin and clopidogrel 
(273,274). Importantly, this increased blood loss has not 
been shown to correlate with increased mortality, ex-
cept in intracranial surgery (267,273). Reports indicate 
an average increase of 30% in the transfusion rate, 
with a complication rate from red blood cell transfusion 
of 0.4% (275) and mortality linked directly to massive 
surgical blood loss in less than 3% of reported clinical 
data (276). However, an important recognized risk of 
withdrawing antiplatelet therapy has been described 
via a rebound effect with increased platelet adhesive-
ness (277-280). This phenomenon is also a consequence 
of the systemic inflammatory response and the acute 
phase reaction to surgery, which also increases platelet 
adhesiveness and decreases fibrinolysis (257,260,281). It 
should also be noted that comorbid pathologies, such as 
carcinoma and diabetes, can also contribute to the pro-
thrombotic state. Death and infarction rates in acute 
coronary syndrome were doubled in the setting of drug 
withdrawal (279). Further, during the important period 
of re-endothelialization after coronary stent implanta-
tion, myocardial infarction rates up to 85% have been 
reported (282), along with a 5-10 fold increase in the 
perioperative mortality. In comparison, existing litera-
ture has reported average stent thrombosis of 35% and 
the average mortality from stent thrombosis of 20% to 
40% (257,283) without noncardiac surgery. 
The questions have been raised in reference to 
withholding antithrombotic therapy prior to interven-
tions and associated risks. Chassot et al (257) proposed 
to modify the practice of withholding patients from all 
antiplatelet agents 7 to 10 days prior to surgery, except 
when bleeding might occur in a closed cavity. Chassot 
et al (257) conducted an extensive review of the litera-
ture and reasoned that in the absence of prior clinical 
data on different antiplatelet regimens during non-
cardiac surgery, including low coronary risk situations, 
patients on antiplatelet drugs should continue therapy 
throughout surgery, except when bleeding might oc-
cur in a closed space. Another proposed consideration 
is the use of a therapeutic bridge utilizing antiplatelet 
drugs with shorter durations of action. In fact, other 
comprehensive reviews have offered variable guid-
ance (27,31,32,34,49,54,124-129,147,149,212,251,284-
299) on anticoagulation management. One systematic 
review (299), which evaluated 31 reports determined 
that for dental procedures, arthrocentesis, cataract 
surgery, and diagnostic endoscopy most patients can 
proceed without alteration to their anticoagulant 
therapy. Several publications also delineated a variety 
of other procedures, including endoscopy (300,301), 
peripheral vascular surgery (302), and ophthalmic 
surgery (303) with no evidence of increased bleeding 
when patients are continued on antiplatelet therapy 
throughout the perioperative period. Gerstein et al 
(304) also showed that for many other procedures, 
minimal perioperative bleeding risk occurred when 
aspirin was continued, contrasted with concomi-
tant thromboembolic risks associated with aspirin 
withdrawal. 
The risk of thromboembolic events may be a more 
significant clinical feature, versus the risk of epidural 
hematoma. A majority of regional anesthesia and in-
terventional pain management literature has focused 
on the risks of epidural hematoma, paying only scant 
attention to thromboembolic events. However, wider 
evidence in the literature defines multiple guidelines 
from other specialties that described continuation of 
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antiplatelet therapy during surgical interventions, in-
cluding peripheral vascular surgery, with some high-risk 
exceptions (267-277,282,299-303,305). 
These data suggest the traditional attitude of 
discontinuing anti-clotting medications 10 days before 
interventions poses considerable clinical risk (268-
273,277,282). Multiple prior guidelines have recom-
mended discontinuation of anti-thrombosis therapy 
and this has shaped general practice to discontinue 
these drugs (40,174,251). Thus, despite absence of evi-
dence of significant bleeding risk during interventional 
techniques in patients with antithrombotic therapy 
(37,251,284,285), they are routinely discontinued. 
Importantly, neither continuation nor discontinua-
tion of antithrombotic therapy comes without risk 
(199,200,212,251,306-311). While most available clinical 
case reports focus on regional anesthesia for surgical 
procedures, additional evidence have been provided 
in the literature relating to epidural hematoma in pa-
tients undergoing interventional techniques for chronic 
pain with or without antithrombotic therapy – contin-
ued or discontinued (31,32,37,38,113-116,182,183,185-
191,193,195,196,199,200,212,251,284,285,306-312). 
In fact, the evidence based on this analysis for 
discontinuing antithrombotic agents is very weak. 
Evidence is stronger for the continuation for antithrom-
botic therapy since the majority of epidural hematomas 
have occured in patients either not on antithrombotic 
agents or in patients whose therapy had been appropri-
ately discontinued. 
6.2 Anatomical Considerations
Multiple factors herein described, including anat-
omy of the epidural space, spinal anatomy, coexisting 
pathology, coagulation status, needle placement, and 
injectate can affect the development of hematomas. A 
meta-analysis of over 600 spinal hematomas including 
both spontaneous and iatrogenic cases, revealed anti-
coagulation to be the second most common underly-
ing etiology, closely following idiopathic occurrence 
without identifiable cause (313). In this meta-analysis, 
spinal and epidural anesthetic procedures in combina-
tion with anticoagulation represented the fifth highest 
cause of epidural hematomas. However, among this 
group of patients, spinal hematomas were most com-
monly encountered in those receiving continuous and 
not single-shot epidural anesthesia (314,315). As shown 
in Table 10, Lagerkranser (52) has shown patient-relat-
ed risk factors in their study of 166 case reports of spinal 
hematoma from 1994 through 2015. Spinal stenosis was 
the most common diagnosis with ankylosing spondylitis 
taking the third place in relation to anatomic factors. 
The evidence from the present analysis also shows 
spinal stenosis as a major risk factor associated with 
technical factors of bleeding and multiple attempts.
6.3 Drug-Related Risk Factors
Drug-related factors are considered to be the most 
common risk factors. Continuation or discontinuation 
of antiplatelets and antithrombotic drugs was reported 
in the majority of the patients in this assessment (63%). 
In addition, earlier studies also showed these as the 
most common risk factors. Lagerkranser (52) described 
drug-related factors as the highest with frequencies as 
shown in Table 11. He reported intake of anti-hemo-
static drugs in 63% of the patients, whereas more than 
one anti-hemostatic drug was implicated in 47 of 166 
cases. 
6.4 Bridge Therapy 
Those undergoing chronic anticoagulation often 
require interruptions due to a procedure or other medi-
cal issue for various durations. The decision to bridge 
with heparin or other anticoagulants is a common clini-
cal problem for those undergoing oral anticoagulation, 
especially in the case of interventional anesthesia. The 
evidence to inform decision making is limited, mak-
ing current guidelines equivocal and imprecise. New 
randomized controlled studies have shown significant 
perioperative or periprocedural bleeding rates without 
reduction in thromboembolism when bridging is com-
pleted (314-317). Additional studies such as PERIOP2 
(318) outlining guidelines for high risk individuals in 
need for bridging have made it somewhat clearer that 
only those with significant thromboembolism risk ben-
efit from bridge therapy. Bridging anticoagulation may 
be vital for patients with a high risk for thromboembo-
lism, but for most patients it produces excessive bleed-
ing which leads to longer hospital stays and significant 
comorbidities without any difference in prevention of 
thromboembolism (319). 
6.5 Reversal of Antithrombotic and 
Anticoagulant Agents
While immediate reversal for interventional pain 
procedures is rare, anticoagulation reversal and treat-
ment options should be discussed in relation to major 
bleeding. Options include protamine, phytonadione 
(Vitamin K), hemodialysis, oral-activated charcoal, 
antifibrinolytic agents including tranexamic acid, 
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desmopressin, blood products including packed red 
blood cells (PRBCs) and platelets, prothrombin complex 
concentrates (PCCs), and specific reversal agents. For 
example, Idarucizumab is the only FDA-approved re-
versal agent for direct oral anticoagulants, specifically 
dabigatran. Andexanet alfa does the same for both 
oral and injectable factor Xa inhibitors. Prothrombin 
complex concentrates have been developed to contain 
highly concentrated coagulation factors along with 
antithrombotic agents. They are quite successful in 
the reversal of vitamin K antagonists (VKAs) and are 
considered first line treatment in patients with major 
bleeding on VKAs. Fresh Frozen Plasma traditionally 
has been used for VKAs as it contains all members of 
the coagulation cascade. It is not as beneficial for direct 
oral anticoagulants as these medications directly tar-
get and inactivate specific factors. The amount of FFP 
needed is estimated to be nearly two liters in order to 
appropriately establish previous concentrations of the 
respective factor (320). 
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